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Abstract
Molecular imaging is making possible the understanding of intricate biological processes in
real-time in both healthy and diseased tissues. The ability to non-invasively locate biomarkers
of disease with good sensitivity and specificity affords the ability to provide accurate and early
diagnoses, and patient stratification for therapy. The chemokine receptor CXCR4 is one
biomarker of interest, as it is overexpressed in many cancers, yet has low expression elsewhere
in normal physiology. This thesis will document a method of combinatorial chemistry to
construct libraries of new potential peptide-based imaging agents for positron emission
tomography (PET) imaging. It will also incorporate the study of strain-promoted alkyne-azide
cycloaddition (SPAAC) as a type of copper-free click chemistry used as a method for
radiofluorination of biological structures.
Chapter 2 discusses the synthesis of a library of N-terminal modified peptides created using a
one-bead one-compound (OBOC) approach. Each peptide in the library contains a single
fluorine atom incorporated through established SPAAC chemistry. The library of complete
imaging agents was put through multiple stages of screening against CXCR4, resulting in the
discovery of a peptide-based imaging agent with an IC50 of 138 µM.
Chapter 3 discusses the development of a new 18F-labelled cyclooctyne-based prosthetic group
for

incorporation

into

azide-functionalized

biological

structures.

This

18

F-

azadibenzocyclooctyne (ADIBO-F) was radiolabelled from its toluenesulfonate precursor in
21–35 % radiochemical yields, and subsequently incorporated into two cancer-targeting
peptides through SPAAC chemistry. The result is two novel peptide‐based PET imaging agents
that possess high affinities for their targets, the growth hormone secretagogue receptor 1a
(GHSR‐1a) and gastrin‐releasing peptide receptor (GRPR), with IC50 values of 9.7 and 0.50
nM, respectively.
Chapter 4 discusses the synthesis of an OBOC library with an imaging moiety integrated
within the peptide structures. A two-pool OBOC strategy was developed to distribute the
fluorine-containing amino acid throughout the peptide sequence during library synthesis. The
ADIBO-F prosthetic group from Chapter 2 was employed for simple translation of peptide
i

hits into their radiofluorinated counterparts. An on-bead two-colour screen was performed in
one step and resulted in the discovery of three CXCR4-specific peptide-based imaging agents
with micromolar affinities of 28, 86 and 109 µM.
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Chapter 1

1

Introduction

1.1 Molecular Imaging
Molecular imaging is a technique that combines molecular biology with non-invasive
medical imaging and can be used to visualize and diagnose a large range of biological
events and pathologies. It is routinely employed in the clinic to give a real-time image of
the presence of important biomarkers or cell processes which allows for early diagnoses
and monitoring of disease progression or treatment efficacy. Preclinical development of
targeted therapeutics and understanding of the role of biomarkers in disease states can also
be guided via molecular imaging.1 Many modalities of molecular imaging, such as
magnetic resonance imaging (MRI) or computed tomography (CT), can rely on inherent
biological contrast to give images with good resolution and specificity. However, some
modalities require the administration of an external agent to provide the information that
is detectable by the instrument of choice. This is particularly important in positron emission
tomography (PET) and single photon emission computed tomography (SPECT) imaging,
where the presence of a radioisotope in the form of a radiopharmaceutical is essential to
the imaging process. Furthermore, the specificity of molecular imaging agents can be
improved by incorporating a targeting portion in addition to the imaging component.
Targeted agents are often designed to bind to cell surface receptors or to be incorporated
into enzymatic processes in the cell (Figure 1.1). The targeting moiety is most often a small
molecule, a peptide, or an antibody, depending on the necessary pharmacokinetics and
distribution for the intended imaging modality.

2

Figure 1.1 Design of a targeted molecular imaging agent.

1.2 PET and Fluorine-18
PET imaging is used for diagnostic imaging applications including oncology and
neurology. It is a vital imaging technique as it offers a limitless depth of penetration, has
high sensitivity, and gives a 3D image wherein the amount of radioactivity can be
quantified using standard uptake values.
As stated, PET imaging requires the presence of a radioactive atom to provide signal. PET
affords us with excellent sensitivity as an imaging modality, as only a small dose of the
radiopharmaceutical is required to give a detectable signal (10-11 -10-12 M). Specifically,
PET imaging requires a radionuclide that emits a positron; nuclei that are commonly used
for PET imaging include 11C, 13N, 15O, 18F, 64Cu, and 68Ga because they decay by positron
emission, also known as β+ decay. All of these radionuclides contain an excess of protons
and decay by converting the extra proton into a neutron (p, n), releasing a positron and a
neutrino. The positron then travels some short distance until it undergoes electron
annihilation and creates two 511 keV gamma-ray photons that are released 180° apart from
one another. PET cameras are set up so that the detectors are ringed around the subject in
order to capture incidences of photons 180° apart. Lines of coincidence are recorded and a
three-dimensional tomographic image with quantitative information can be constructed
based on annihilation locations of coincident photon events.
As previously discussed, there are multiple options of radioisotopes for PET, however
fluorine-18 has chemical and physical characteristics that make it a preferred radioisotope
for PET imaging. Fluorine-18 is routinely produced in a cyclotron by bombarding

18

O-

enriched water with high-energy protons, making it comparatively easily accessible and

3

inexpensive to produce. Compared to other organic radioisotopes, 18F has a longer half-life
of 109.8 minutes, which is generally sufficient to provide time for synthesis, delivery, and
imaging without significant decay. Fluorine-18 also decays almost entirely by β+ decay
(97%), making it an ideal isotope for PET imaging because the high quantity of annihilation
events allows for high molar activities. Beyond the physical properties of fluorine-18, there
are chemical properties that are considered beneficial over metallic radioisotopes that
require chelation systems for incorporation into biomolecules. Fluorine is relatively small;
this makes it a superior option in applications with small molecules in order to reduce steric
bulk. Moreover, fluorine is most often introduced into molecules in the form of a stable
carbon-fluorine bond which makes it more stable in vivo leading to low potential of
radioactive accumulation in off-target tissues. An important consideration is the rapidity of
incorporating the fluoride so that radiolabelling is facile and time-considerate. The
synthetic conditions required to directly fluorinate targeting entities with [18F]fluoride are
often too harsh for biomolecule-based targeting moieties. A few notable exceptions include
non-canonical 18F-labelling strategies involving isotope exchange reactions from fluorine19 precursors, and aluminum fluoride constructs, which can all be achieved under mild
conditions.87-89 Another common route is to incorporate

18

F through a small molecule

prosthetic group which is radiolabelled first and then attached to the biomolecule through
milder reaction conditions. The radiochemical reactions to attach the prosthetic group must
be rapid and involve minimal or simple purification steps. These include nucleophilic
substitution (SN2) reactions, Michael additions, or click chemistry.
fluorine-18 prosthetic groups are shown in Figure 1.2.2

Some common

4

Figure 1.2 Representative examples of common 18F prosthetic groups for straightforward
labelling of biomolecules.

1.3 Click Chemistry
Click chemistry is a recently explored family of reactions, where the reaction method is
rapid, bioorthogonal, produces no or harmless by-products, and can be conducted in
physiologically friendly reaction conditions (physiological pH, room temperature, aqueous
solution). The classic click chemistry reaction first introduced by Sharpless is the coppercatalyzed Huisgen cycloaddition of an alkyne and an azide to produce a 1,4-triazole.3 This
reaction is extensively used in radiolabelling and imaging because of its fast reaction rates.
Additionally, amino acids with an azido or alkyne side chain are often incorporated into
peptides and antibodies for easy modification with complementarily functionalized
imaging entities ‒ generally fluorescent dyes. However, the cytotoxicity of residual copper
is a concern in bio-applications,4 leading to research into copper-free click chemistry.
The most prominent developments for copper-free click chemistry include Bertozzi’s
Staudinger ligation,5 strain-promoted alkyne-azide cycloaddition (SPAAC),6,7 and inverse
electron demand Diels-Alder (iEDDA).8,9 All of these reactions are used mostly for
biological applications with nuclear imaging being an especially important area of research
because the mild reaction conditions are desirable for radiolabelling. Of these copper-free
click techniques, we chose to invest in SPAAC chemistry, as the reaction rates favour
radiolabelling strategies and the components could be easily modified to suit our needs.
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1.4 Strain-Promoted Click Chemistry
SPAAC enlists the help of a strained alkyne in order to lower activation energy
requirements of the click reaction and increase the rate constant. The reaction typically
takes place between a strained alkyne and an organic azide (Figure 1.3). The 160° angle
introduced to the sp-hybridized carbons of the alkyne by constraining it into an eightmembered ring induces sufficient polarization for it to react without a copper catalyst,
unlike a terminal alkyne. Additionally, electron-withdrawing groups can be added to the
cyclooctyne to further lower the energy of the LUMO (lowest unoccupied molecular
orbital).10,11

Figure 1.3 Mechanism of the strain-promoted alkyne-azide cycloaddition reaction.
SPAAC has rate constants of around 0.076 M-1 s-1 (difluorinated cyclooctyne, DIFO)11 to
0.96 M-1 s-1 (biarylazacycloooctyne, BARAC)12 for different cyclooctynes (Figure 1.4),
generally measured with the standard of benzyl azide in CD3OD or CD3CN. These numbers
average out to be lower compared to those of iEDDA and normal copper-catalyzed click
reactions, but higher than those of the Staudinger ligation. Some cyclooctynes employed
in SPAAC increase strain through a fused cyclopropyl ring at the base, such as in
bicyclononyne (BCN).13 The highest rate constants come from further strained
cyclooctynes, such as those with benzene fused to either side of the eight-membered ring.
BARAC is one of these alkynes ‒ with the quickest rate constant reported to date of 0.96
M-1 s-1.12 However this also comes with a loss of stability; rearrangement often occurs in
these structures over time.14 Azadibenzocyclooctynes (ADIBO or DIBAC) have a less
ideal rate constant of around 0.31 M-1 s-1 but comes with much better shelf and solution
stability.15 Variations on the structure of ADIBO, in which more electron-withdrawing
groups have been added, are also seen to improve rate constants.16 Unfortunately, these
modifications introduce synthetic complexity, which limits their availability. An acid or
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amine handle incorporated into the R group in ADIBO provides a mode of bioconjugation
for peptides and other biologically relevant structures.

Figure 1.4 Structures of common cyclooctynes used in SPAAC chemistry.
An inherent fault in SPAAC reactions using ADIBO and most other cyclooctynes is that
two regioisomers are produced that are difficult to separate (Figure 1.5). For
radiochemistry applications, the lengthy separation especially becomes an issue with the
need for short syntheses to prevent radioactive decay. Some cyclooctynes, like BCN, do
not form regioisomers but can create equally undesirable diastereomers or enantiomers.13
Some work has been done with various cyclooctynes in which bulky functional groups are
selectively placed near one side of the alkyne in order to favour one regioisomeric product
due to steric bulk limitations.17,18 Similarly, Gröst and Berg reported a cyclooctyne that
offers a single product with no isomers, although its reaction kinetics are not particularly
impressive.19

Figure 1.5 Regioisomers produced by SPAAC of ADIBOs.
Nonetheless, SPAAC employing ADIBO has seen use for radiolabelled and biological
applications. In a few cases,
steps to produce a

18

18

F is integrated into a cyclooctyne structure over multiple

F-cyclooctyne prosthetic group (Figure 1.6A), to which an azide-

7

containing targeting entity is then clicked.20–24 More commonly, the

18

F is incorporated

into an azide functionalized small molecule (Figure 1.6B), followed by a click reaction
with an ADIBO-functionalized biological entity.25,26

Figure 1.6 A variety of 18F prosthetic groups used in SPAAC radiochemistry.27

1.5 Peptides as Targeting Moieties
Peptides are especially useful as targeting components of radiopharmaceutical imaging
agents.28 Their size and connectivity give them relatively short biological half lives that
match the radioactive half lives of isotopes used. Because they circulate and clear quickly,
this results in lower background levels of signal in PET or SPECT imaging. In addition,
peptides are often highly selective and specific for their target. Peptide ligands for targeting
can be discovered through rational design, where the side chains of the peptide sequence
can be chosen based on the desired interactions with the known microenvironment in a
binding pocket of a biological target. For targets of high complexity or with an unknown
microenvironment, combinatorial methods are also used to discover novel peptide
sequences. Although peptides are not usually very stable in biological conditions due to
proteolysis, simple modifications to make the structures less like those of natural peptides
are often employed, including amidation or acetylation of the C- and N-terminals, and
incorporation of D-amino acids, unnatural amino acids or non-amino acid components.
Many prosthetic groups are amenable to incorporation into peptides via coupling of free
amines or carboxylic acids in the peptide structure.
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Solid-phase peptide synthesis (SPPS) allows for straightforward synthesis and simple
modifications of peptide structures. The approach uses an orthogonal protecting group
strategy in order to couple amino acids one at a time onto a growing peptide chain built on
resin from the C- to N- terminus. The fluorenylmethyloxycarbonyl protecting group
(Fmoc) is base-labile and used to protect backbone amino groups on amino acids
introduced. Various acid-labile protecting groups are used to protect side chain functional
groups. Each amino acid is successively coupled to the amino-terminal of the growing
peptide using a coupling reagent to form an active ester of the amino acid being introduced.
Fmoc-removal using piperidine is then performed to generate a free amine for the next
coupling step. Because the peptide is built on-resin, unused reagents and byproducts are
washed away between steps. Final cleavage from the resin and side-chain protecting group
removal can be afforded under acidic conditions (Figure 1.7).

Figure 1.7 Scheme depicting the basic steps of Fmoc-based solid-phase peptide synthesis
on an amine-functionalized resin.

1.6 One-Bead One-Compound Libraries
One-bead one-compound (OBOC) libraries and phage-display libraries are both
combinatorial methods which allow the high-throughput screening of a diverse population
of peptides against a target.29 These biologically active peptides can then later be
conjugated to an imaging moiety to form a targeted imaging agent.30 OBOC libraries are a
combinatorial method in which SPPS is used to produce a large number of chemically
unique peptides each formed in multiple copies on a single resin bead. The process was
developed by Kit Lam in 1991 as a method to rapidly chemically synthesize a large library
of randomized peptides for screening for biological activity.31 Importantly, unlike many
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other options to synthesize large libraries of peptides, such as phage display, OBOC can
easily incorporate D-amino acids, unnatural amino acids, other small molecular weight
components, and can overcome other limitations inherent of biological selection bias.
Although OBOC libraries have been employed to discover new peptides that target cancer,
among other diseases,29,32–39 there are relatively few reports of these peptides successfully
modified into imaging agents.30,33,40–45 For direct identification of potential imaging agents,
the integration of an imaging surrogate before screening for biological activity should be
performed. This process would allow the imaging portion of the agent to be incorporated
into the binding pocket of the target protein during solid-phase affinity studies. Peptide
sequences where the imaging portion would prevent binding are excluded before further
synthesis and complex binding assays. Conversely, peptides that bind better with the
imaging portion present compared to the unmodified peptide would now be included in
further studies. Whereas, when using the classic approach where the imaging moiety is
added post-screening, these unmodified peptides may not have been included after the
initial screen. To our knowledge, only three examples have been reported in the literature
of such an approach, whereby the OBOC library consisted of imaging agents. In two cases,
the design of such libraries was described: an N-terminally modified Re(CO)3
organometallic peptide library was developed in our lab for the discovery of 99mTc SPECT
imaging agents;46 and the synthesis of a peptoid DOTA-containing OBOC library for
different metal chelates was described towards application for PET or MRI imaging. 47 A
recent publication describes the creation and on-bead screening of a focused OBOC peptide
library containing the αvβ6‐targeting motif and a C-terminal 4-fluorobenzoyl group, which
had some success in the discovery of lead peptides towards new 18F imaging agents.48
An OBOC library is created by splitting the resin into n equal portions in n wells. To each
well a different Fmoc-protected amino acid is added, along with the necessary coupling
reagents. After coupling is achieved, the resin from all of the wells are combined, Fmocdeprotected, and split back into n wells. Subsequent coupling and deprotecting is
performed and this process is repeated until the desired length of peptide is obtained
(Figure 1.8). By splitting the resin in this way, the possibility for a bead to host a mixture
of peptides is eliminated, and so each bead contains solely multiple copies of a single entity.
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Figure 1.8 Two cycles of split-and-mix in forming an OBOC library using amino acids
A, C, D, E, and F.
This split-and-mix technique allows the diversity of the library to grow exponentially with
each coupling step. For example, a library of octamers created from 17 different amino
acids would result in a theoretical diversity of 178 ‒ around 7 billion possible unique peptide
sequences. Since the amount of resin typically used is only 1 g (around 1.5 million
TentaGel beads), less than 0.1% of possible peptides are expressed. This suggests that there
is likely no redundancy in the library. Generally, some amino acids such as cysteine are
excluded from those employed in the library so as to avoid complications such as crosslinking. Likewise, methionine is also often not used because of its ability to easily become
oxidized. Once the library has been synthesized, all remaining amino acid side-chain
protecting groups are cleaved by an acidic solution, while the peptide stays attached to the
resin through some linker. These linkers can be stable, or cleaved orthogonally through
chemistries such as photolabile or disulfide linkers.49,50
To screen the millions of peptides created from an OBOC library, the beads holding the
peptides are combined with a biological entity of interest. A known target is not necessary,
as often phenotypic screens are performed on cells. Specific targets can be used by either
isolating a protein or by overexpressing the target in a cell line. The protein or cell line is
generally fluorescently labelled in order to have the ability to detect the peptide beads that
have binding interactions. Unbound cells or protein are washed away and beads are sorted
based on affinity to the target. Alternatively, a protein linked to a magnetic bead could also
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be used for screening and sorted from unbound library beads by a magnet in a “beads on a
bead” approach.51,52
Several approaches for sequence deconvolution of peptide hits exist, although it still
remains the most laborious and challenging part of the OBOC screening process. Classical
techniques included Edman degradation which is costly, time-consuming and is limited for
peptides without N-terminal modifications or unnatural modifications in the peptide
backbone.

Matrix-assisted

laser

desorption/ionization

(MALDI)

tandem

mass

spectrometry (MS/MS) has emerged as a more rapid and cost-effective method to
determine peptide sequences, and has no limits based on modifications, but has its own
limitations based on fragmentation and ionization efficiency (Chapter 1.7). New
technology has allowed for other emerging methods of deconvolution. One-bead twocompound (OBTC) bilayer approaches to chemically encoding beads involves parallel
synthesis of small amounts of another molecule with the peptide53,54; these can even be
oligonucleotides that can later be amplified by PCR and used to relate the DNA sequence
to the corresponding amino acids used in the peptide construction.55 Ladder-synthesis
approaches cap small amounts of peptide after each coupling, which leaves behind partial
sequences that are more reliably observed in MS than peptide fragments via MS/MS.56,57
Perhaps the most exciting recent advance in the field is the development of RFID-tagged
chips that can be followed through each split-and-mix step for immediate and reliable
identification of hit sequences, although this capability is still limited to smaller sized
libraries.58

1.7 Matrix-Assisted Laser Desorption/Ionization Mass
Spectrometry
MALDI is a frequently used tool for de novo sequencing of unknown peptides in either an
on-bead process developed previously in our lab,50 or once the peptide has been
photocleaved from the peptide into solution. This technique is often used over techniques
like Edman degradation or OBTC because it is fast, cheap, and consistent. It also allows
the recovery of small quantities of the peptide once completed. Cruikshank et al. reported
the ability to sequence N-terminally modified Re-complexed peptides by MALDI MS/MS
at single bead quantities of peptide.46
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Tandem mass spectrometry is performed by selecting for the complete peptide at a
determined parent ion m/z, fragmenting the peptide in the collision cell, and then collecting
a complete mass spectrum of the fragments produced. In peptides, the location of the most
common cleavage in low energy collisions is at the amide bonds between amino acids.
Since almost each amino acid has a specific mass to charge ratio (m/z) for their residue, the
mass difference between fragment peaks can be used to determine the amino acid sequence.
Because this fragmentation produces both ionized fragments containing the N-terminus of
the peptide or containing the C-terminus, it results in two series of peptide fragments
detectable by MS/MS. The y ion series describes the result of amino acid loss from the Nterminus. This means that all the fragments retain the original C-terminus of the peptide
and the fragments have a charged N-terminus. Similarly, the b ion series reflects the result
of amino acid cleavage from the C-terminus. All fragments in the b series retain the Nterminus of the peptide and contain a charged C-terminus. An extension of the b series is
also sometimes seen in lower incidence than b or y ions, wherein further fragmentation of
the b series ions has occurred through the loss of a carbonyl; this is called the a ion series
(Figure 1.9).59
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Figure 1.9 A general hexamer peptide structure showing common fragmentation
locations and examples of the fragments that are produced.
Because this fragmentation occurs randomly within the peptide, some fragments may not
appear in the MS/MS spectra with significant intensity. Because of this, sequencing by
MALDI often has a low success rate. However, as long as there is sufficient overlap
between the two series, full sequence deconvolution of the peptide is possible.
Another difficulty encountered in sequencing by MS/MS lies in isobaric amino acids (those
with similar masses such as leucine and isoleucine, or glutamine and lysine). Often, only
one of the two matching amino acids are employed in the library. This unfortunately limits
the structural diversity in peptides that could be generated in the library. Alternatively,
peptides hits that include these mass residues can be resynthesized using either amino acid
in the location of question and further screening can be performed with both options of
which the sequences are now known.
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1.8 G Protein-Coupled Receptors as Biological Targets
G protein-coupled receptors (GPCRs) are a class of proteins with seven transmembrane
domains. Because they are cell-surface receptors they are designed to detect extracellular
molecules to start signal transductions within the cell, which makes them well-suited as
biological targets for imaging agents. Their cell surface binding site allows for easy
accessibility of the targeting entity which means imaging agents do not need to be cell
permeable. Internalization through the receptor can occur, which often does lead to
increased uptake of the tracer. Because GPCRs are such a large class of proteins, almost
34% of FDA approved drugs target GPCRs, which means many are well-characterized and
their roles in disease states have been explored.60 An important GPCR studied in cancer
imaging is the gastrin-releasing peptide receptor (GRPR, also known as BB2) due to its
high levels of overexpression in various cancers. The peptide bombesin has been found to
bind to GRPR with high affinity and has been derivatized and used in multiple nuclear
imaging applications.26,61–63 Our lab has also explored the growth hormone secretagogue
receptor (GHSR-1a) as a target due to its differential expression in prostate cancer over
benign prostate tissues.64 The endogenous ligand for GHSR-1a is the peptide ghrelin, and
previous efforts in our lab have established ghrelin peptide analogues that can be modified
with fluorescent dyes or radioligands for imaging.65–67

1.9 C-X-C Chemokine Receptor 4
The chemokine receptor CXCR4 is a GPCR that was first identified as a route of entry for
HIV infection into CD4+ cells. Its natural ligand is CXCL12 (also known as SDF-1α), and
together they are involved in various cellular pathways including chemotaxis, angiogenesis
and proliferation. Although this receptor has relatively low expression in normal tissues,
it is expressed in over 23 types of cancers including breast and prostate cancer and
melanomas.68 The expression of CXCR4 has been linked to metastatic forms of cancer due
to its role in chemotactic pathways and homing to lymph nodes and bone marrow. It was
determined in clinical prostate cancer biopsies that although the expression of CXCR4 is
not significantly associated with Gleason score, frequency of CXCR4 expression is 35
times higher in prostate cancer than non-malignant prostate tissue.69 Imaging of CXCR4 is
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therefore an exciting target that could prove to be important for diagnoses and stratification
of malignant and metastatic cancers.
All forays into imaging CXCR4 have stemmed from research into anti-HIV-1 drugs.
Antimicrobial self-defense peptide polyphemusin II was identified from the extracts of
horseshoe crab (Tachypleus tridentatus) hemocytes.70 This peptide and its derivatives were
found to be effective at inhibiting HIV-1 entry into cells via CXCR4.71 The peptide is 18
amino acids in length, contains two disulfide bonds to form a beta-hairpin structure, and is
amidated at the C-terminus. Initial structure-activity studies in order to improve potency
and reduce cytotoxicity identified a peptide termed T22 (Tyr5,12, Lys7).72 Efforts to shorten
the peptide and maintain potency eventually resulted in T140, a 14 amino acid peptide with
a carboxylic acid C-terminus and a single disulfide bridge that retains high CXCR4 affinity
(Figure 1.10a).73 FC131 is a cyclic pentapeptide which is the result of structure-activity
studies to determine the main binding residues of T140; the N-terminal arginine,
naphthylalanine, and tyrosine were found to be important for CXCR4 affinity (Figure
1.10b).74 In addition, small molecule AMD3100 (Plerixafor) was also explored for its use
as an HIV inhibitor as it is known to block the CXCR4 receptor but has since been used to
treat cancer patients by mobilizing hematopoietic stem cells for transplantation (Figure
1.10c).75,76

Figure 1.10 CXCR4-targeting ligands with high affinities A) peptide T140 B) cyclic
peptide FC131 C) AMD3100.
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Of the PET imaging agents developed for CXCR4, T140 has been most often used as the
scaffold of choice. In the first attempts to create a CXCR4 imaging agent, T140 was
labelled on the N-terminus with various prosthetic groups. The use of [18F]4-fluorobenzoyl
resulted in extremely high non-CXCR4 specific binding to red blood cells (RBCs) which
proved not useful for imaging.77 Modifications of T140 with DOTA or NOTA for

68

Ga,

64

Cu, and [18F]AlF incorporation lowered binding to RBCs but had significant liver and

kidney uptake (up to 30% ID/g) and a decreased CXCR4 affinity.78–80 N-terminal
acetylated T140 derivatives were also labelled on the Lys7 residue with [18F]2fluoropropionyl or [18F]4-fluorobenzoyl groups, showing lower blood retention, good
CXCR4 affinity, but still high liver and kidney retention.81 Co-injection with excess cold
tracer was shown to decrease liver uptake, which proves that the uptake is receptor-specific,
but this strategy is not realistic for imaging purposes. FC131 has been modified to contain
a DOTA chelator which was radiolabelled with

68

Ga while retaining excellent CXCR4

affinity.82 This radiopharmaceutical, called Pentixafor, is now being used in humans to
image a variety of CXCR4-expressing cancers.83,84 A fluorine-18 labelled analogue
utilizing [18F]AlF chemistry is being evaluated as an alternative.90 FC131 has also been
labelled via a click reaction on a side chain with [18F]fluoroethylazide, which resulted in a
poorer CXCR4 binder than FC131 on its own, and has not yet been explored for in vivo
biodistribution or imaging.85 AMD3100 labelled with

64

Cu has also shown promise as a

PET imaging agent targeting CXCR4, but also has high liver uptake due to its positively
charged nature, as well as issues with tumour to background ratios from plasma protein
binding and potential transchelation of the metal.86
Unfortunately, many of these peptide-based imaging agents, especially those employing
fluorine-18, display poor pharmacokinetics and biodistribution in vivo which can likely be
attributed to being based on the same peptide structure which carries through the
physicochemical profile. New CXCR4-binding peptide-based imaging agents could be
discovered through combinatorial methods and would likely result in a different
pharmacokinetic profile.

1.10 Summary
The discovery of new peptide-based ligands for cancer targeting is important for the
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development of the field of molecular imaging. OBOC libraries are often employed to
discover such ligands. However, the addition of an imaging component to the peptide can
often be detrimental to the binding affinity of the peptide sequence. To overcome this
obstacle, we propose to integrate the imaging surrogate in the library prior to screening.
We can discover new peptide-based imaging agents by screening a fluorine-containing
OBOC library against a target of choice, wherein the imaging component of the molecule
is essential to the binding affinity. Fluorine-18 radiochemistry is often performed through
the use of click chemistry such that radiolabelling is fast, clean and simple. OBOC peptide
libraries containing a clicked cyclooctatriazole moiety will be prepared so that a
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F-

labelled version would be easily prepared through SPAAC. The target of interest for this
project is CXCR4, which has been implicated as a receptor highly expressed in various
solid cancers. Although some CXCR4 imaging agents have been developed, they all stem
from the same natural peptide structure which has resulted in a poor biodistribution profile
common amongst all designs. An OBOC library of imaging agents could be used to screen
for new CXCR4-targeting ligands. This will lead to the discovery of new fluorine-18 PET
imaging probes for CXCR4-expressing cancers.
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Chapter 2

2

Incorporation of Fluorine into an OBOC Peptide Library
by Copper-free Click Chemistry towards the Discovery
of PET Imaging Agents

2.1 Introduction
New peptide-based imaging agents can be developed by rational design from known targetspecific peptides or through combinatorial methods. The synthesis of one-bead onecompound (OBOC) libraries is a combinatorial method introduced by Lam et al. in 19911
which involves split-and-mix synthesis to create millions of candidates from which
peptide-receptor interactions can be discovered. Although the screening of classic OBOC
libraries produces target-specific peptides,2–6 post-identification modification of these
peptides to convert them into imaging agents often decreases binding affinity and creates
the necessity for further modifications.7–11 However, few ventures have been made into
making OBOC libraries of imaging agents.12–14
Fluorine-18 is a preferred radioisotope for positron emission tomography (PET) imaging
due to its half-life and availability; as such, incorporating a 19F-moiety into each entity of
an OBOC library would create a library of complete imaging agents. This allows the
imaging portion of the agent to be incorporated into the binding pocket of the target protein
during affinity studies. Peptide sequences where the imaging portion would prevent
binding would be excluded before further synthesis and complex binding assays.
Conversely, peptides that bind better with the imaging portion present compared to the
unmodified peptide are now included in further studies. This enables high-throughput
screening of millions of potential imaging agents. Tang et al. recently created a focused
OBOC peptide library containing the αvβ6‐targeting motif and with a C-terminal 4fluorobenzoyl group and had some success in the discovery of lead peptides towards new
18

F imaging agents.14

In this work, we aimed to develop an entirely randomized OBOC library containing an Nterminal functionalized fluoride-containing moiety in hopes of producing imaging agents
where the imaging portion is involved in receptor binding itself. Copper-free click
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chemistry by strain-promoted alkyne-azide cycloaddition (SPAAC)15 is an increasingly
popular technique for incorporating radioisotopes into biomolecular targeting agents due
to its quick and mild reaction conditions.16–18 By using cyclooctyne-modified peptides and
an azide-containing

19

F-prosthetic group, this would allow for efficient and simple

radiolabelling to produce the eventual 18F-imaging agent for PET imaging.
The chemokine receptor CXCR4 has been implicated as a receptor of interest in a wide
variety of cancers, especially in advanced and metastatic stages.19 Current peptide-based
18

F PET imaging agents that target CXCR4 have been based on the CXCR4-antagonist

peptide T140, which was developed from the natural peptide polyphemusin II.20
Unfortunately, many of these imaging agents display poor pharmacokinetics and
biodistribution in vivo.21–24 New CXCR4-binding peptide-based imaging agents could be
discovered through combinatorial methods.
Our unique combinatorial library was screened on-resin against a U87 cell line that highly
expresses CXCR4; beads that showed binding to the cells were isolated, and the sequences
of the respective peptide portions were identified by MALDI tandem mass spectrometry
(MS/MS). This demonstrates a methodology where novel fluorine-containing peptidebased imaging agents can be discovered with straightforward translation into

18

F PET

imaging agents of CXCR4-expressing cancer.

2.2 Results and Discussion
2.2.1
The

Design and Synthesis

cyclooctyne

moiety

chosen

for

the

construction

of

our

library

was

azadibenzocyclooctyne-acid (ADIBO-COOH) 2.1 and was synthesized according to the
methods of Chadwick et al.25 We chose to employ a PEG-based azide-containing

18

F

prosthetic group in order to offer some hydrophilicity to balance the large hydrophobic
cyclooctyne. The fluorine-19 analogue 2.2 was synthesized and used in the construction of
our library. An entirely randomized octamer OBOC library was synthesized on one gram
of Tentagel S resin equipped with a photocleavable linker ((3‐amino‐3‐(2‐nitrophenyl)propionic acid) (ANP)). This allows protecting groups to be removed while the
peptides stay attached to the resin beads; yet, the peptides can be later removed from resin
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for sequencing. Seventeen natural amino acids (excluding cysteine, methionine, and
isoleucine) were used in the split-and-mix process, after which the “clicked” portion 2.3
was coupled onto the N-terminal of the combined library (Scheme 2.1). The result is a pool
of about 1.5 million potential imaging agent candidates in which there is likely no
redundancy of peptide sequences (less than 0.1% of potential diversity explored).

Scheme 2.1 Synthesis of an octamer library on Tentagel resin using ADIBO-COOH 2.1
and a PEG-based azide-containing fluoride 2.2. X is any natural amino acid excluding
cysteine, methionine, and isoleucine.

2.2.2

Library Screening and Sorting

The deprotected library beads were subjected to screening against U87.CD4.CXCR426
cells that had been pre-incubated with a green Cell Tracker dye (ThermoFisher) to afford
a way to visualize and sort the beads. In multiple wells the entire library was screened;
approximately 500,000 cells were incubated with 20,000 beads in 3 mL of media per well
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for one hour at 37 ⁰C. After incubation, some wells were visualized under fluorescence
microscopy to confirm interactions between the cells and beads. Receptor-peptide
interactions between the cells and beads were fixed with 4% paraformaldehyde, excess was
quenched with 2 M glycine. Library beads were then recombined, media was decanted,
and the beads were resuspended in PBS.
Beads were sorted in aliquots using a Complex Object Parametric Analyzer and Sorter
(COPAS, Union Biometrica)27 through two screening steps. Initially, all beads were
collected that expressed any threshold of green fluorescence (dye λex/em = 492/517 nm)
which resulted in narrowing the library hits to approximately 2,500 beads. This pool,
however, can include false positive beads that exhibit autofluorescence of the Tentagel
bead. These beads were then subjected to a second round of sorting by the COPAS with
the green fluorescence threshold set to a higher limit (Figure 2.4). Hit beads during this
step were sorted individually into 96 well plates and around 200 beads were collected.
Visualization of the wells was performed under fluorescence microscopy to remove any
remaining false positive results that were incorrectly identified as hits during the automated
COPAS sort due to high levels of bead autofluorescence (Figure 2.5). Remaining beads
were swollen in water and placed under a UV lamp for two hours in order to cleave peptides
off the beads. The supernatant was then subjected to MALDI MS/MS for peptide sequence
deconvolution (Figure 2.1).
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2.2.3

MALDI MS/MS Deconvolution of Hit Peptide Sequences

Figure 2.1 MALDI MS/MS deconvolution of a peptide hit from library screen; showing
overlapping b and y series of fragments and demonstrating high fragmentation at b0. The
isobaric amino acids lysine (K) and glutamine (Q) are both possibilities for mass
fragments of ~ 128 Da.
This step of the process proved challenging where some wells produced no observable MS
product (possibly due to insolubility, incomplete cleavage from bead, etc.), or incomplete
fragmentation in MS/MS leading to unsolvable sequences (a known issue in this
deconvolution technique).28–30 In addition, the isobaric amino acids lysine and glutamine
were both used in this library to promote diversity, but the corresponding residue mass was
often observed in MS/MS spectra, which lead to multiple possible iterations of the hit from
a single bead. An unexpected issue that arose was the high frequency of fragmentation
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between the N-terminal amino acid and the imaging portion (at b0), causing less intense
fragmentation patterns along the rest of the peptide backbone.

2.2.4

Hit Peptide Synthesis and Validation of Target Specificity

In the end, hit sequences that could be fully identified (Table 2.1) were resynthesized on
Tentagel resin, including all possible combinations with Lys/Gln. Evaluation of each hit
sequence using bulk beads allowed for a final determination of which peptide sequence
iteration was legitimately a sequence that interacts with CXCR4. Peptides on resin were
incubated with a single sequence in individual wells with either fluorescently-tagged
U87.CXCR4.CD4 cells or U87.CD4 cells to serve as a control. Wells were imaged by
fluorescent microscopy to re-confirm CXCR4 affinity and to select for peptides with
CXCR4 selectivity. This step serves to remove any remaining false positives and to identify
peptides that had off-target binding to the cells. Figure 2.2 displays an example where the
four possible iterations of the ‘hit’ sequence shown in Figure 2.1 were synthesized
separately on Tentagel resin. Of the combinations, only one (-YKFKRLWP-) shows good
affinity to the CXCR4-expressing cells as well as strong selectivity for CXCR4 compared
to the control cell line (cells in the top right image are in the background and not adherent
to the beads). The other sequences show either low affinity, poor selectivity, or both.
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Figure 2.2 On-bead screen of potential hits synthesized on Tentagel of the sequence
F-PEG2-ADIBO-YXFXRLWP-NH2 where X = Q or K. This screen allows for
confirmation of ‘hit’ sequence when isobaric amino acids are involved and also screens
for selectivity to the target.

2.2.5

Hit Peptide Synthesis and Validation of Target Affinity

CXCR4-selective peptides were then resynthesized on Rink-amide resin and purified as
the C-terminal amide. These peptides were subjected to a competitive binding assay using
U87.CD4.CXCR4 cells and [125I]-SDF-1α as the radioligand. The lead compound from this
target affinity assay was identified as F-PEG2-ADIBO-YKFKRLWP-NH2 and has an IC50
of 138 µM. While other

18

F peptide-based imaging agents for CXCR4 have higher

affinities, they are primarily based on the same polyphemusin peptide sequence and often
have comparable drawbacks when it comes to in vivo behaviour.21–24 This OBOC library
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produced a new sequence that can serve as a starting point for further development towards
novel CXCR4-targeted imaging agents.

2.3 Conclusions
Overall, we have developed an OBOC approach as a combinatorial method to produce a
large-scale library of peptide imaging agent candidates. This can be useful for the screening
against any target of interest for imaging purposes. Our library conveniently includes the
chosen imaging moiety (fluorine-18, with fluorine-19 as a standard) through copper-free
click chemistry in order to produce hits that can be easily translated into radiolabelled
imaging agents. Although the discovery of imaging agents from this method still proves to
be laborious and fraught with challenges, the screening steps directly produced a lead
imaging agent with micromolar affinity Modifications based on this sequence could be
explored to further improve the affinity for CXCR4. Exciting new advancements in
technologies for tracking synthetic histories of solid-phase syntheses with DNA tags or
RFID microtransponders are highly complementary to this sort of application.31,32 As
Improvements upon some of the challenges encountered in this library development will
be explored in future generations of OBOC imaging agent libraries. Focused library
synthesis would aid in the throughput of sequence deconvolution when part of the sequence
is known, as well as likely produce higher affinity hits.5,14 Other library conformations
where the imaging moiety is dispersed through the peptide sequences could also be
explored to promote discovery of imaging agents where the imaging moiety is integrated
into the binding pocket.

2.4 Experimental
2.4.1

General Experimental

All reactions were carried out under a nitrogen atmosphere using oven-dried glassware.
Dichloromethane (DCM) was distilled over CaH2. Other reagents and solvents were used
as received from Sigma-Aldrich, Alfa Aesar, or Fisher Scientific. Amino acids and resins
were received from Peptides International or Chem. Impex.. Flash chromatography was
performed on a Biotage Isolera Prime automated flash purification system. Biotage SNAP
KP-Sil 10 g, 25 g, or 50 g cartridges (45-60 micron) were used with flow rates of 12, 25,
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and 50 mL/min respectively for gradient solvent systems. Fractions were monitored and
collected by UV absorbance using the internal UV detector set at 254 nm and 280 nm.
NMR spectra were recorded on a either an Agilent Mercury VX 400 or a Bruker AvIII HD
400 MHz Spectrometer. Chemical shifts are recorded in parts per million. EI and CI HRMS
was measured on a Thermo Scientific DFS (Double Focusing Sector) mass spectrometer.
Peptides were purified by preparative reverse-phase HPLC-MS and analytical reversephase HPLC-MS was performed to assess purities. The system consists of a Waters 600
controller, Waters Prep degasser, Waters Quattro micro Mass, and Waters Mass Lynx
software. The UV absorbance was detected using a Waters 2998 Photodiode array detector.
A preparative column (Agilent Zorbax PrepHT SB-C18 Column 21.2 x 150 mm, 5 µm) or
analytical column (Agilent Zorbax SB-C18 column 4.6 x 150 mm, 5 µm) was used. The
solvent system runs gradients of 0.1 % trifluoroacetic acid (TFA) in ACN and 0.1 % TFA
in water at a flow rate of 20 mL/min or 1.5 mL/min over 10 minutes with a 5 minute wash.
After purification, the collected fractions were frozen at -78 °C and lyophilized.

2.4.2

Small Molecule Synthesis

5-[11,12-Didehydrodibenzo[b,f]azocin-5(6H)-yl]-4-oxobutanoic Acid (ADIBOCOOH) (2.1)
ADIBO-COOH 2.1 was prepared as described by Chadwick et al.25 1H NMR (400 MHz,
CDCl3): δ 7.67 (d, J = 7.5 Hz, 1H), 7.50 – 7.20 (m, 7H), 5.16 (d, J = 13.9 Hz, 1H), 3.70 (d,
J = 13.9 Hz, 1H), 2.72 (ddd, J = 16.6, 8.9, 5.2 Hz, 1H), 2.60 (ddd, J = 17.0, 8.9, 5.2 Hz,
1H), 2.36 (ddd, J = 16.8, 6.4, 5.1 Hz, 1H), 1.99 (ddd, J = 16.6, 6.6, 5.2 Hz, 1H).13C NMR
(100 MHz, CDCl3): δ 176.1, 172.6, 151.2, 147.8, 132.4, 129.3, 128.7, 128.6, 128.5, 128.03,
127.4, 125.7, 123.2, 122.8, 115.2, 107.6, 55.8, 29.7, 29.6. HRMS (EI): m/z calculated for
C19H15NO3 : 305.1052; found: 305.1045.
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Scheme 2.2 Scheme for synthesis of 2.2.
2,2’-(ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl)bis(4-methylbenzenesulfonate) (2.4)
Tosyl chloride (7.61 g, 39.9 mmol) was slowly added to a solution of triethylene glycol
(2.00 g, 13.3 mmol) in triethylamine (50 mL). The reaction mixture was stirred overnight
at room temperature, and the solvent was removed by rotary evaporation. The product was
washed with water and extracted into EtOAc. The combined organic layers were dried over
MgSO4 and concentrated under reduced pressure. The product was isolated by automated
Isolera flash column chromatography (SNAP KP-Sil cartridge, 12-100% EtOAc/hexanes)
yielding the ditosyl 2.4 (2.77 g, 63%) as an orange solid. 1H NMR (400 MHz, CDCl3): δ
7.77 (d, J = 8.0 Hz, 4 H), 7.33 (d, J = 8.0 Hz, 4 H), 4.12 (t, J = 4.8 Hz, 4 H), 3.63 (t, J =
4.8 Hz, 4 H), 3.50 (s, 4 H), 2.42 (s, 6 H).

13

C NMR (100 MHz, CDCl3): δ 145.0, 133.0,

129.9, 128.0, 70.7, 69.3, 68.8, 21.7. HRMS (EI): m/z calculated for C20H26O8S2 : 458.1069;
found: 458.1079.
2-(2-(2-azidoethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (2.5)
A solution of ditosyl 2.4 (90.0 mg, 1.96 mmol) and sodium azide (113 mg, 1.72 mmol) in
dry DMF (5 mL) was stirred at room temperature overnight. The reaction mixture was
quenched with water and extracted into DCM. The organic fractions were washed with
water, brine, and dried over MgSO4. The combined organic layers were concentrated under
reduced pressure and the product was isolated by automated Isolera flash column
chromatography (SNAP KP-Sil cartridge, 17-100% EtOAc/hexanes), yielding the azide
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2.5 (57.0 mg, 81%) as a yellow oil. 1H NMR (400 MHz, CDCl3): δ 7.89 (d, J = 8 Hz, 2 H),
7.34 (d, J = 8 Hz, 2 H), 4.16 (t, J = 5 Hz, 2 H), 3.70 (t, J = 5 Hz, 2 H), 3.64 (t, J = 5 Hz, 2
H), 3.60 (s, 4 H), 3.36 (t, J = 5 Hz, 2 H), 2.44 (s, 3 H). 13C NMR (100 MHz, CDCl3): δ
144.9, 133.1, 129.9, 128.1, 70.9, 70.7, 70.2, 69.4, 68.9, 50.8, 21.8. HRMS (CI): m/z
calculated for C13H20N3O5S [M+H]+ : 330.1118; found: 330.1123.
1-azido-2-(2-(2-fluoroethoxy)ethoxy)ethane (2.2)
A commercially available solution of 1.0 M TBAF in THF (6.94 mL, 6.94 mmol) was
added to a solution of azide 2.5 (1.14 g, 3.47 mmol) in t-BuOH (30 mL). The reaction
mixture was stirred at 100 °C overnight. The reaction mixture was quenched with water
and extracted into DCM. The combined organic layers were dried over MgSO4 and
concentrated under reduced pressure. The product was purified by automated Isolera flash
column chromatography (SNAP KP-Sil cartridge, 0-2% MeOH/DCM), yielding the
product 2.2 (390 mg, 64%) as a pale yellow oil. 1H NMR (400 MHz, CDCl3): δ 4.60 (t, J
= 2.8 Hz, 1 H), 4.52 (t, J = 2.8 Hz, 1 H), 3.77 (t, J = 2.8 Hz, 1 H), 3.72 (t, J = 2.8 Hz, 1 H),
3.70-3.66 (m, 6 H), 3.38 (t, J = 3.2 Hz, 2 H). 13C NMR (100 MHz, CDCl3): δ 83.3 (d, 1JCF
= 169 Hz), 71.0, 70.9, 70.7 (d, 2JCF = 19.6 Hz), 70.3, 50.8. HRMS (CI): m/z calculated for
C6H12FN3O2 [M+H]+ : 178.0986; found: 178.0990.
F-PEG2-ADIBO-COOH (2.3)
ADIBO-COOH 2.1 (0.158 g, 0.52 mmol) and 2.2 (0.115 g, 0.65 mmol) were dissolved in
5 mL of a 3:2 EtOH:H2O mixture. The solution was shaken for two hours, diluted with
water, frozen, and lyophilized. The product was purified as a combination of its two
inseparable regioisomers by automated Isolera flash column chromatography (SNAP KPSil cartridge, 2-15% MeOH/DCM) to yield 2.3 as a yellow oily solid (0.200 g, 80%). 1H
NMR (400 MHz, CDCl3) δ 7.91 – 7.07 (m, 8H), 6.12 (d, J = 16.7 Hz, 1H), 4.73-4.64 (m,
1H), 4.60-4.51 (m, 2H), 4.50 – 4.43 (m, 1H), 4.43 (d, J = 16.6 Hz, 1H), 4.02-3.91 (m, 2H),
3.79 – 3.69 (m, 2H), 3.69 – 3.55 (m, 4H) 2.58 – 2.26 (m, 2H), 2.0 (m, 1H), 1.99 – 1.62 (m,
1H). HRMS (EI): m/z calculated for C25H27FN4O5 : 482.1965; found: 482.1972.
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2.4.3

OBOC Library Synthesis

The library was synthesized using standard Fmoc solid-phase peptide synthesis (SPPS)
conditions on a Biotage SyroWave automated peptide synthesizer using a split-and-mix
technique in the dark. Briefly, 1 g of Tentagel S-NH2 resin (90 µm, 0.29 meq/g) was
swelled in DCM and manually coupled to Fmoc-ANP-OH linker (4 eq) using HCTU (4
eq) and N-N-diisopropylethylamine (DIPEA) (8 eq) in DMF for two hours. The resin was
split into seventeen vessels. Fmoc removal was achieved using 40% piperidine in
dimethylformamide (DMF) over two steps (5 min and 15 min). Each well was coupled to
a different Fmoc-amino acid (4 eq) using HCTU (4 eq) and DIPEA (8 eq) in DMF for one
hour. After each Fmoc-deprotection/coupling cycle, the resin was recombined into one
pool and then divided into seventeen vessels again. This was repeated eight times to
achieve peptides eight amino acids in length. To the combined library, F-PEG2-ADIBOCOOH 3 (1.6 eq) was coupled using HATU (1.6 eq) and DIPEA (3.2 eq) in DMF for 5
hours. Full deprotection was achieved with 95% TFA, 2.5% triisopropylsilane (TIPS) and
2.5% water for 5 hours. The library was rinsed thoroughly with DMF, DCM, MeOH, and
stored in 70% EtOH/H2O.

2.4.4

Hit Peptide Synthesis

Peptides were synthesized using standard Fmoc SPPS conditions on the Biotage SyroWave
automated peptide synthesizer. Fmoc-protected Rink amide MBHA or Tentagel S- NH2
resin was used as a solid support after swelling in DCM. Fmoc removal was achieved using
40% piperidine in dimethylformamide (DMF) over two steps (30 sec and 12 min). Amino
acids were coupled with the Fmoc-protected amino acid (4 eq), HCTU (4 eq) and DIPEA
(8 eq) in DMF/N-methyl pyrrolidinone (NMP) over 1 hour. The acid 2.3 was manually
coupled to the N-terminus using 1 equivalent of 2.3, 1 equivalent of HATU and 2
equivalents of DIPEA in DMF.
Tentagel peptides were deprotected using a solution of 95% TFA, 2.5% TIPS and 2.5%
water for 4 hours. Beads were rinsed thoroughly with DMF, DCM, MeOH, H2O and stored
in 70% EtOH/H2O.
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Full cleavage of the Rink-amide peptides from resin along with removal of side chain
protecting groups was achieved with a solution of 95% TFA, 2.5% TIPS and 2.5% water
over 5 h. The cleaved peptides were precipitated in cold tert-butyl methyl ether (TBME)
and centrifuged at 3000 rpm for 15 min. The TBME was decanted, the peptide dissolved
in water, frozen at -78 °C and lyophilized. The peptides were then purified by preparative
reverse-phase HPLC-MS over gradients of acetonitrile (0.1% TFA) in water (0.1% TFA).
The peptides were isolated in >98% purity by analytical RP-HPLC. Peptides are a
combination of the two inseparable regioisomers.
Table 2.1 Sample list of select peptide sequences resynthesized for in vitro validation.
All are coupled to 2.3 on the N-terminal and are amidated on the C-terminal.
Amino Acid Sequence

[M+H]+ m/z theoretical

[M+H]+ m/z found

-YKFKRLWP-

1600.86

1600.83

-HLTKYWET-

1540.74

1540.55

-HLTQYWET-

1540.70

1540.50

-AKEDNFRN-

1456.68

1456.54

-AQEDNFRN-

1456.64

1456.47

-NDEDEEYA-

1447.54

1447.39

-RLDSHDPK-

1430.70

1430.56

-RLDSHDPQ-

1430.66

1430.51

-NFKEFDHA-

1452.69

1452.53

-NFQEFPHA-

1452.65

1452.45

-FLFWGPAG-

1357.65

1357.52

37

Default file
em-iii-97G qc 25to85-Agilent feb2-17
9.55

2: Diode Array
Range: 1.884

1.4

1.2

AU

1.0

8.0e-1

6.0e-1

4.0e-1

2.0e-1

7.01
0.97

0.0
0.00

2.00

4.00

6.00

8.00

10.00

Time
12.00

Figure 2.3 Sample HPLC chromatogram (UV trace, 25-85% ACN/H2O with 0.1% TFA)
of a purified peptide F-PEG2-ADIBO-YKFKRLWP-NH2.

2.4.5

Cell Culture

U87.CD4 and U87.CD4.CXCR4 cells were obtained through the NIH AIDS Reagent
Program, Division of AIDS, NIAID, NIH from Dr. Hong Kui Deng and Dr. Dan R.
Littman. U87.CD4.CXCR4 cells were maintained in DMEM – high glucose (Sigma)
containing 15% fetal bovine serum (FBS), 1 μg mL-1 puromycin, 300 μg mL−1 G418, and
1× penicillin–streptomycin. U87.CD4 cells were maintained in DMEM – high glucose
(Sigma) containing 10% FBS, 300 μg mL−1 G418, and 1× penicillin–streptomycin. All cell
lines were cultured at 37 °C in humidified atmosphere with 5% CO2 and passaged 2 to 3
times per week.

2.4.6

Library Screening

U87.CD4.CXCR4 cells at 80% confluency were incubated with 5 µM CellTracker™ Green
CMFDA Dye (ThermoFisher) in serum-free DMEM media for 30 min at 37 °C. Dye was
aspirated, and cells were lifted using an enzyme-free dissociation solution (Sigma). Cells
were counted and resuspended in serum-free DMEM at 500,000 cells/mL. Library beads
were suspended in phosphate-buffered saline (PBS) and dispersed in 6-well plates at
~20,000 beads/well (entire library is ~1.5 million beads). Cells were added to each well (1
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mL, 500,000 cells) and total volumes were brought up to 3 mL with DMEM. Plates were
shaken at 550 rpm for 1 hour at 37 °C. To each well, 0.33 mL of 37% paraformaldehyde
was added for a final concentration of 4%. Fixing was quenched by the addition of 2 M
glycine to a final concentration of 20%. The entire library of beads was recombined and
rinsed with PBS repeatedly then suspended in PBS. Aliquots of this solution were added
to the sample cup of a COPAS instrument (Union Biometrica) and diluted into the
appropriate sheath reagent. Beads were sorted at ~20 events/s and excited by a 488 nm
lamp to select for beads (via length (TOF) and optical density (Ext)) as well as to sort for
fluorescence (green λem = 510±23 nm) (Figure 2.4A-B & 2.5A-B). Beads were collected in
bulk (~2500 events), rinsed, and then re-added to the sample cup and sorted with a higher
set threshold of fluorescence for sorting (Figure 2.4C). In this sort, hit beads were deposited
into individual wells of a 96 well plate (~200 events) (Figure 2.5C-D). Wells were imaged
by confocal fluorescent microscopy to remove any remaining false positive beads (Figure
2.5D). Confocal fluorescence microscopy was performed on a Nikon A1R Confocal Laser
Microscope with a 488 nm laser for excitation and the emission range set to 500-550 nm.

Figure 2.4 Screenshots of COPAS software showing A) gating selection for bead-sized
objects based on size (TOF) and optical density (Ext); B) sorting selection for initial
screen based on bead size and above-average green fluorescence (λem = 510±23 nm); C)
sorting selection for second round with higher threshold of green fluorescence.
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Figure 2.5 Confocal fluorescence images of A) library pool after incubation with
U87.CD4.CXCR4 cells tagged with CellTracker Green CMFDA; B) library beads after
initial screen showing some hit beads with various degrees of cell coverage; C) isolated
hit library bead in a well of a 96 well plate after second sorting round; D) isolated false
positive bead displaying high autofluorescence.

2.4.7

MALDI MS/MS

Hit beads from the library screen were suspended in 50 µL of water in individual wells of
96-well plates and placed under UV light (365 nm) for 2 hours to achieve cleavage from
the bead due to the ANP linker. The aqueous solution was mixed with matrix α-cyano-4hydroxycinnamic acid (CHCA) in acetonitrile and placed onto the MALDI target. MALDI
TOF/TOF was performed on an AB Sciex TOF/TOF 5800 by the facility manager of the
MALDI Mass Spectrometry Facility at the London Regional Proteomics Centre.

2.4.8

Selectivity Analysis Assay

U87.CD4.CXCR4 or U87.CD4 cells at 80% confluency were incubated with 5 µM
CellTracker™ Green CMFDA Dye (ThermoFisher) in serum-free DMEM media for 30
min at 37 °C. Dye was aspirated, and cells were lifted using an enzyme-free dissociation
solution (Sigma). Cells were counted and resuspended in serum-free DMEM at 150,000
cells/mL. Tentagel beads expressing re-synthesized potential hit sequences were suspended
in phosphate-buffered saline (PBS) and dispersed in 12-well plates at ~10,000 beads/well.
Cells were added to each well (1 mL, 150,000 cells) and total volumes were brought up to
2 mL with DMEM. Plates were shaken at 550 rpm for 1 hour at 37 °C. Wells were directly
imaged using confocal fluorescent microscopy (Nikon).
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Figure 2.6 Uncropped Images of Figure 2.2 to further display selectivity.

2.4.9

Competitive Binding Assays

In vitro CXCR4 affinity of final hit peptides were determined through competitive binding
assays using U87.CD4.CXCR4 cells with [125I]-SDF-1α as the radioligand (Perkin Elmer).
The compound of interest (30 µL, at concentrations ranging from 10−6 to 10−2 M) and
20,000 cpm of [125I]-SDF-1α (20 pM) were mixed with the binding buffer (20 mM HEPES,
0.5% BSA in PBS, pH 7) in 1.5 mL Eppendorf Protein LoBind vials. A suspension of
U87.CD4.CXCR4 cells (50,000 cells in 50 µL) was added to each vial to give a final
volume of 300 μL. The vials were shaken at 550 rpm for 20 minutes at 37 °C. Immediately
after the incubation, the vials were centrifuged at 13,000 rpm for 5 minutes and the
supernatant removed. The cell pellet was washed with 500 μL of 50 mM Tris buffer (pH
7) and centrifuged again. The amount of [125I]-SDF-1α bound to the cells was measured

41

using a gamma counter (PerkinElmer). IC50 values were determined by non-linear
regression analysis to fit a 4-parameter dose response curve using GraphPad Prism
(Version 6.0c). All data points were obtained in triplicate.
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Chapter 3

3

A Compact and Synthetically Accessible Fluorine-18
Labelled Cyclooctyne Prosthetic Group for Labelling of
Biomolecules by Copper-free Click Chemistry

3.1 Introduction
Positron emission tomography (PET) is an important molecular imaging technique used to
non-invasively visualize and diagnose many different biological events and pathologies.1
The use of fluorine-18 as a PET radionuclide is popular due to its relatively long half life
(~110 minutes) among non-metallic isotopes, allowing ample time for radiosynthesis as
well as other favourable nuclear and chemical properties.2 Due to its small size, fluorine18 has been incorporated into imaging agents of various complexities from small molecules
to larger biomolecules.3-5 However, an important consideration is the method of
incorporating the fluoride such that rapid and facile radiolabelling is achieved. Direct
labelling of a molecule with fluoride-18 can require harsh nucleophilic conditions, which
the biologic “targeting” portion of an agent may not withstand. Instead, small-molecule
fluorine-18 prosthetic groups are labelled first and used to introduce the radionuclide to a
biomolecule under milder conditions. Careful selection of these prosthetic groups is
necessary to ensure that the addition does not elicit a change in biological function.
The copper-catalyzed alkyne-azide 1,3-dipolar cycloaddition (CuAAC) reaction as a form
of “click chemistry” was first introduced by Sharpless in 2001.6 This concept has since
been widely explored in applications to label biomolecules with various imaging
components under bioorthogonal conditions. The click reaction satisfies the requirement
of milder reaction conditions for appending a prosthetic group to a biomolecule; it also
boasts the benefits of fast reaction kinetics and lack of by-products. Because of these
properties, this reaction lends itself particularly well to synthetic radiolabelling strategies
for the production of nuclear imaging agents.7 This is especially true for shorter-lived PET
isotopes such as fluorine-18. For the use of CuAAC in in vivo applications, the complete
removal of copper reagents remaining after reactions is necessary in order to avoid
cytotoxicity issues. These extra purification steps unfortunately hinder the efficiency of the
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radiosynthesis. The strain-promoted alkyne-azide cycloaddition (SPAAC) reaction is a
convenient copper-free alternative to click chemistry reactions which avoids cytotoxic
copper reagents.8
Both CuAAC and SPAAC have been extensively used to label biomolecules such as
proteins, oligonucleotides, peptides and other targeting entities with fluorine-18.9-13 In
SPAAC examples, the most commonly used cyclooctynes are azadibenzocyclooctynes
(ADIBOs), due to their relatively fast reaction kinetics (0.4-0.9 M-1s-1 depending on
modifications) and long-term stability compared to other reported cyclooctynes.14-15
ADIBO is commonly synthesized with an acid or amine handle, which allows for
conjugation to biomolecules through standard coupling techniques (Figure 3.1A).
Fortunately, there have been a wide variety of fluorine-18 azide-containing prosthetic
groups developed for copper-catalyzed click reactions which are also employable with
cyclooctyne-modified biomolecules, allowing for quick transition into PET imaging
agents.16

Figure 3.1 Structures of A) non-labelled ADIBOs where R contains an acid or amine for
conjugation to a biomolecule, B) ADIBOs that have been indirectly labelled with
fluorine-18 and C) ADIBOs that have been further derivatized into fluorine-18 prosthetic
groups.
To approach radiolabelling via the SPAAC reaction from the opposite direction, easilyaccessed azide-containing biomolecules and targeting moieties can be employed. The
complementary piece to this azido-derivatized biomolecule necessitates an
cyclooctyne.

18

F-labelled
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Indirect labelling of ADIBOs was first shown by using the prosthetic group 4succinimidyl-[18F]fluorobenzoate to incorporate fluorine-18 into an amine-functionalized
ADIBO (Figure 3.1B).17-18 ADIBOs have also been shown to be sufficiently stable for
direct fluorine-18 labelling conditions. Previous approaches in the literature make use of
ADIBO-NH2 by coupling a carboxylic acid-functionalized linker to the amine tail. This
alkyl or PEG linker connects the ADIBO to a suitable leaving group for

18

F-labelling of

the resulting molecule (Figure 3.1C).19-20 Recently, an oxodibenzocyclooctyne was
labelled with fluorine-18 showing reactivity with micromolar concentrations of azidemodified bioconjugates.21 While these are exciting and useful developments for the
utilization of copper-free click techniques in fluorine-18 radiolabelling of peptides, these
constructs can be fairly large and high in molecular-weight for a prosthetic group. Because
the copper-free click reaction is not regioselective, this long tail also results in significantly
different 1,4 and 1,5 regioisomers, which could affect receptor binding or pharmacokinetic
properties of the imaging agent. Furthermore, the expense of ADIBO-NH2 and ADIBOCOOH can be prohibitive when investigating the discovery of new imaging agents. We
propose a new fluorine-containing ADIBO that seeks to: 1. simplify synthesis from
inexpensive, readily-available starting materials; 2. minimize structural difference in
regioisomers produced by the SPAAC reaction; 3. reduce the size and molecular weight of
the prosthetic group in comparison to those previously reported.

3.2 Results and Discussion
3.2.1

Synthesis of ADIBO-F

We report a new fluorine-containing ADIBO that is synthetically accessible in nine linear
steps via modifications to the Popik synthesis.22-23 In brief, the inexpensive starting
material dibenzosuberenone 3.1 was converted to oxime 3.2. A subsequent Beckmann
rearrangement produces lactam 3.3, which is then reduced by lithium aluminum hydride to
its secondary amine 3.4. The amine is acylated with bromoacetyl bromide to produce 3.5
with a handle for functionalization from the azadibenzocyclooctene core. Compound 3.5
is subsequently transformed into the alcohol 3.6, which is stable to the reaction conditions
used for the formation of the cyclooctyne. Bromination across the cyclooctene and
subsequent elimination with potassium tert-butoxide produces the cyclooctyne 3.7.
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Tosylation of the alcohol to produce a suitable leaving group results in the precursor of the
prosthetic group 3.8. Conversely, the fluorine-19 standard of the prosthetic group can be
formed by halide exchange of the bromide 3.5 to fluoride using tetrabutylammonium
fluoride to produce 3.9. This can be followed by a similar bromination/elimination of the
cyclooctene to form the cyclooctyne 3.10 (Scheme 3.1).

Scheme 3.1 Branching synthesis of both ADIBO-OTs 3.8 and [19F]ADIBO-F 3.10
standard via modifications to the Popik synthesis22-23 of ADIBOs.
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3.2.2

Radiolabelling of a [18F]ADIBO-F Prosthetic Group

The tosylate precursor 3.8 of this novel ADIBO has been labelled with dry [18F]fluoride
under basic conditions in the presence of Kryptofix 222. The prosthetic group [18F]3.10
was purified by semi-preparative HPLC and isolated in greater than 98% radiochemical
purity to give 21-35% decay-corrected radiochemical yields in under 30 minutes of total
reaction and purification time (Scheme 3.2).

Scheme 3.2 Radiosynthesis of [18F]ADIBO-F [18F]3.10.

3.2.3

Copper-Free Click Radiolabelling of Model Peptides using
[18F]ADIBO-F

The potential for [18F]ADIBO-F [18F]3.10 to be employed as a prosthetic group has been
tested with two peptides that are known to be effective for targeting G protein-coupled
receptors (GPCRs) overexpressed in a variety of cancers. The first example of using our
novel prosthetic group for radiolabelling is demonstrated by incorporating it into [Dpr3

(octanoyl),Lys19]ghrelin(1-19). It has been shown that peptides with various imaging

moieties connected at the Lys19 of this peptide sequence target the GHSR-1a receptor with
nanomolar affinities.24-26 By modifying Lys19 to a lysine-azide (3.11), imaging moieties can
be linked to the peptide by click reactions resulting in candidate imaging agents. Through
triazole formation at the azide, our new cyclooctyne prosthetic group was linked to this
peptide in 15 minutes at 70 °C, which is milder than typical nucleophilic fluoride addition
conditions. The SPAAC reaction allows this labelling to proceed in neutral conditions in
absence of any other reagents, and at a temperature that allows for increased reaction
kinetics while ensuring peptide stability. Full radiochemical conversion was observed at
this temperature with no remaining prosthetic group or production of radioactive byproducts.

The product, [18F][Dpr3(octanoyl),Lys19(triazole-ADIBO-F)]ghrelin(1-19)

[18F]3.12, was isolated by semi-preparative HPLC resulting in good radiochemical yields

48

of 64-66% of the isolated product in greater than 98% radiochemical purities (Scheme 3.3).
The SPAAC reaction was performed with quantities less than 200 MBq of the prosthetic
group, resulting in molar activities of 0.6-0.9 GBq/µmol for the isolated product.

Scheme 3.3 Strain-promoted alkyne-azide cycloaddition of [18F]ADIBO-F prosthetic
group [18F]3.10 with an azide-modified ghrelin peptide 3.11. Only one regioisomer of
[18F]3.12 is shown for simplicity.
A non-radioactive fluorine-19 containing analogue of 3.12 was synthesized to serve as a
reference standard. Co-injection of the nonradioactive standard 3.12 with the labelled
peptide [18F]3.12, in addition to an overlay of the UV chromatogram for the standard and
the radio-chromatogram of the labelled peptide confirms the success of the radiolabelling
SPAAC reaction (Figure 3.2). Interestingly, the two regioisomers produced had no
distinguishable difference in retention times, even with various HPLC gradients, reflecting
the minimal structural difference between these regioisomers.
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Figure 3.2 Overlaid analytical C18 RP-HPLC chromatograms at 25 to 80% (ACN/H2O,
0.1% TFA) over 15 minutes of purified peptide [18F]3.12 (solid trace, radiochromatogram) and its non-radioactive [19F]3.12 analogue (dashed trace, UV
chromatogram, λ = 220 nm).
Using the nonradioactive 3.12, an IC50 of 9.7 nM was obtained from a competitive binding
assay for the receptor GHSR-1a. This value is comparable to that of similar known ghrelintargeting imaging probes (9.5-25.8 nM)24-25 (Figure 3.9) and shows that this peptide
maintains a strong affinity for the receptor of interest with the addition of our new
prosthetic group, making it potentially suitable as a cancer-targeting PET imaging probe.
The stability of the fluorine towards hydrolysis was assessed using a 1 mg/mL solution of
3.12 in water at 37 °C over 24 h. No degradation of the peptide or fluoride lability was
observed as indicated by HPLC-MS analysis.
In a similar manner, [D-Phe6,β-Ala11,Phe13,Nle14]bombesin(6-14) is known to target all
four of the gastrin-releasing peptide receptor (GRPR) subtypes with sub-nanomolar
affinities.27 An N-terminal modification of bombesin-targeted peptides does not disrupt
affinity,28-31 therefore [D-Phe6,β-Ala11,Phe13,Nle14]bombesin(6-14) with an azido-PEG8
linker on the N-terminus was synthesized and linked to [18F]ADIBO-F in the same process
as described above resulting in full radiochemical conversion and excellent isolated
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radiochemical yields for this step of 81-88%. The labelled peptide was purified by semipreparative RP-HPLC in greater than 98% radiochemical purities and molar activities of
0.6-1.1 GBq/µmol. The non-radioactive standard of this peptide was used to validate the
identity of the labelled peptide by co-injection and for in vitro studies (Chapter 3.4). This
modified peptide-based imaging agent maintained a high affinity to the GRPR receptor
with an IC50 value of 0.50 nM, which is comparable to that of the unmodified bombesin
peptide (0.70 nM) (Figure 3.10).
Table 3.1 Characterization of the 18F-labelled ghrelin and bombesin peptides.

Peptide

[18F][Dpr3(octanoyl),Lys19(triazoleADIBO-F)] ghrelin(1-19)

[18F][D-Phe6,βAla11,Phe13,Nle14]bombesin(614)-PEG8(triazole-ADIBO-F)

Target
Receptor

GHSR-1a

GRPR

IC50[a] (nM)

9.7

0.5

Azido-Peptide
Concentration
(mM)

3.7

5.6

Yields[b] (%)

64-66

81-88

Purities[c] (%)

>98

>98

Molar
Activities[d]
(GBq/µmol)

0.6-0.9

0.6-1.1

[a] Determined using the 19F standard analogue. [b] Decay-corrected radiochemical yields
for isolated products. [c] Radiochemical purity by analytical RP-HPLC. [d] Determined by
analytical HPLC area under the curve (AUC) at 220 nm of an aliquot of the isolated
fraction. (n=3 for all values)

3.3 Conclusions
We have reported a novel ADIBO-F and its tosylate precursor which can be synthesized
on the side chain of the ADIBO core structure with minimal additional sterics or molecular
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weight. The tosylate precursor is accessible in a scalable synthetic procedure over eight
steps in 15% overall yield from inexpensive starting materials via modifications to the
Popik synthesis. The radiolabelling of the [18F]ADIBO-F precursor was carried out
efficiently in yields of 21-35% and isolated for use as a prosthetic group in approximately
an hour from fluoride-18 trapping. The availability of a minimally-sized ADIBO-based
fluorine-18 prosthetic group in the radiolabelling toolbox allows for copper-free click
labelling of a wide range of biomolecules and targeting moieties for PET imaging agents.
As proof-of-principle this prosthetic group’s utility was shown by incorporating it into two
different cancer-targeting peptides. These reactions were carried out in high yields with
simple and quick purifications. The entire two-step labelling process can be performed
manually within two hours including purifications resulting in good molar activities. The
excellent radiochemical yields of this click reaction in mild, aqueous reaction conditions
lends itself favourably to the labelling of sensitive biomolecules.
This novel cyclooctyne prosthetic group demonstrates a new, rapid labelling option for the
incorporation of fluorine-18 into azide-containing biomolecules to make imaging agents.

3.4 Experimental
3.4.1

General Experimental

All reactions were carried out under a nitrogen atmosphere using oven-dried glassware.
Dichloromethane (DCM) was distilled over CaH2. Other reagents and solvents were used
as received from Sigma-Aldrich, Alfa Aesar, or Fisher Scientific. Amino acids and resin
were received from Peptides International or Chem. Impex.

QMA carbonate SPE

cartridges were purchased from Waters. [125I]-Ghrelin and [125I]Tyr4-bombesin were
purchased from Perkin Elmer. Flash chromatography was performed on a Biotage Isolera
Prime automated flash purification system. Biotage SNAP KP-Sil 10 g, 25 g, or 50 g
cartridges (45-60 micron) were used with flow rates of 12, 25, and 50 mL/min respectively
for gradient solvent systems as specified. Fractions were monitored and collected by UV
absorbance using the internal UV detector set at 254 nm and 280 nm. NMR spectra were
recorded on a Bruker 400 MHz Spectrometer. Chemical shifts are referenced to the residual
solvent peaks and recorded in parts per million. ESI HRMS was measured on a Bruker
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microOTOF 11. EI and CI HRMS was measured on a Thermo Scientific DFS (Double
Focusing Sector) mass spectrometer. Peptides were purified by preparative reverse-phase
HPLC-MS and analytical reverse-phase HPLC-MS was performed to assess purities. The
system consists of a Waters 600 controller, Waters Prep degasser, and Waters Mass Lynx
software. The UV absorbance was detected using a Waters 2998 Photodiode array detector.
A preparative column (Agilent Zorbax PrepHT SB-C18 Column 21.2 x 150 mm, 5 µm) or
analytical column (Agilent Zorbax SB-C18 column 4.6 x 150 mm, 5 µm) was used. The
system runs gradients of 0.1% trifluoroacetic acid (TFA) in ACN and 0.1% TFA in water
at a flow rate of 20 mL/min or 1.5 mL/min over 10 minutes with a 5 minute wash. After
purification, the collected fractions were frozen at -78 °C and lyophilized.
Cyclotron-produced [18F]fluoride was obtained from Dr. Mike Kovacs at the Cyclotron &
PET Radiochemistry Facility at St. Joseph’s Hospital in London, Ontario, Canada.
Analytical radio-RP-HPLC (Agilent RP-C18 column 4.6 x 150 mm, 5 µm) and
semipreparative RP-HPLC (Agilent RP-C18 column 19 x 150 mm, 5µm) were performed
on a Waters 1525 Binary HPLC Pump containing a Waters 2487 dual λ absorbance detector
(292 and 220 nm), Waters InLine degasser, a gamma detector and Breeze software. This
system runs gradients of 0.1% trifluoroacetic acid (TFA) in ACN and 0.1% TFA in water
at a flow rate of 1.5 mL/min or 4 mL/min.

3.4.2

Small Molecule Synthesis

5H-Dibenzo[a,d]cyclohepten-5-one oxime (3.2)
Following a literature procedure,23 dibenzosuberenone 3.1 (7.14 g, 34.6 mmol) and
hydroxylamine hydrochloride (3.60 g, 51.9 mmol) were dissolved in pyridine (30 mL) and
stirred under reflux for 24 h. The reaction mixture was concentrated under reduced pressure
and the residue was poured into ice cold 5% HCl (150 mL) and stirred vigorously for 30
min at 0 °C. The white precipitate was collected by filtration, washed with water, and dried
in vacuo, yielding oxime 3.2 (7.46 g, 97%) as an off-white powder. 1H NMR (400 MHz,
CDCl3): δ 9.32 (br s, 1 H), 7.69-7.67 (m, 1 H), 7.62-7.58 (m, 1 H), 7.46-7.34 (m, 6 H), 6.94
(d, J = 12 Hz, 1 H), 6.90 (d, J = 12 Hz, 1 H). 13C NMR (100 MHz, CDCl3): δ 156.6, 135.5,
134.6, 133.8, 130.8, 130.7, 130.5, 129.5, 129.2, 129.1, 129.0, 129.0, 128.9, 127.8, 127.7.
MS (EI): m/z calculated for C15H11NO : 221.0841; found: 221.0821.
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Dibenzo[b,f]azocin-6(5H)-one (3.3)
According to a procedure by Chadwick et al.23 with slight modifications, Eaton’s reagent
(P2O5/MeSO3H, 20 mL) was added to a flask containing oxime 3.2 (3.00 g, 14.1 mmol).
The reaction mixture was stirred at 100 °C for 2 h. The reaction was quenched with water
(65 mL) and extracted into hot EtOAc multiple times. The combined organic layers were
concentrated under reduced pressure and cooled. The precipitate was filtered (G4 fritted
filter) and washed with cold EtOAc. The lactam 3.3 (2.63 g, 89%) was obtained as a light
grey powder. 1H NMR (400 MHz, CDCl3): δ 7.73 (br s, 1 H), 7.47 (dd, J = 7.6, 1.2 Hz, 1
H), 7.32-7.23 (m, 2 H), 7.22-7.11(m, 4H) 7.05 (dt, J = 7.6, 0.6 Hz, 1 H), 6.96 (d, J = 11.8
Hz, 1 H), 6.85 (d, J = 11.8 Hz, 1 H). 13C NMR (100 MHz, CDCl3): δ 173.7, 135.4, 135.3,
134.8, 134.2, 133.2, 129.8, 129.7, 129.3, 128.5, 128.4, 128.2, 127.8, 127.2, 126.4. HRMS
(EI): m/z calculated for C15H11NO : 221.0841; found: 221.0849.
5,6-Dihydrodibenzo[b,f]azocine (3.4)
From a slight modification to a procedure by Chadwick et al.,23 a dry flask was charged
with lactam 3.3 (5.00 g, 22.6 mmol) and LiAlH4 (8.58 g, 226 mmol) and flushed with N2.
Dry Et2O (50 mL) was added slowly and the mixture was subsequently stirred under reflux
for 12 h. The reaction mixture was cooled at 0 °C, diluted with DCM (100 mL), and
carefully quenched by the dropwise addition of water. Additional water was added (50
mL), and the white inorganic precipitate was removed by filtration. The organic layer was
extracted from water with additional DCM, dried over MgSO4, and concentrated under
reduced pressure, yielding amine 3.4 (4.25 g, 91%) as a bright yellow solid. 1H NMR (400
MHz, CDCl3): δ 7.30-7.18 (m, 4 H), 7.00 (dd, J = 7.8, 1.6 Hz, 1 H), 6.91 (m, 1 H), 6.64
(m, 1 H), 6.56 (d, J = 13.3 Hz, 1 H), 6.47 (dd, J = 8.1, 1.2 Hz, 1 H), 6.38 (d, J = 13.3 Hz,
1 H), 4.58 (s, 2 H).
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C NMR (100 MHz, CDCl3): δ 147.2, 139.3, 138.2, 134.8, 132.8,

130.2, 129.0, 128.0, 127.7, 127.4, 121.8, 118.0, 117.8, 49.6. HRMS (EI): m/z calculated
for C15H13N : 207.1048; found: 207.1056.
(Z)-2-bromo-1-(dbenzo[b,f]azocin-5(6H)-yl)ethenone (3.5)
To a solution of amine 3.4 (500 mg, 2.41 mmol) and triethylamine (488 mg, 4.82 mmol)
in dry DCM (10 mL), bromoacetyl bromide (973 mg, 4.82 mmol) was added dropwise.
The solution was stirred for 1 h at room temperature. The reaction mixture was diluted with
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DCM, and washed with 1 M HCl (3x), 2 M NaOH (3x), water and brine. The organic
fraction was dried over Na2SO4, and concentrated under reduced pressure. The product 3.5
was obtained as a yellow oil (744 mg, 94%). 1H NMR (400 MHz, CDCl3): δ 7.32-7.26 (m,
5H), 7.21-7.11 (m, 3H), 6.84 (d, J = 12.9 Hz, 1 H), 6.66 (d, J = 12.6 Hz, 1 H), 5.42 (d, J =
14.9 Hz, 1 H), 4.32 (d, J = 14.9 Hz, 1 H), 3.58-3.52 (m, 2 H). 13C NMR (100 MHz, CDCl3):
δ 166.2, 140.0, 136.6, 136.5, 133.8, 133.1, 131.6, 131.2, 130.7, 128.7, 128.7, 128.0, 128.0,
127.6, 127.5, 55.3, 27.7. HRMS (EI): m/z calculated for C17H14BrNO : 327.0259; found:
327.0251.
(Z)-1-(dibenzo[b,f]azocin-5(6H)-yl)-2-hydroxyethanone (3.6)
A mixture of 3.5 (795 mg, 2.42 mmol) and potassium formate (1.22 g, 14.5 mmol) was
refluxed in dry methanol for 12 hours. The mixture was diluted with water, extracted into
DCM, was washed with brine. The organic fraction was dried over Na2SO4, and
concentrated under reduced pressure. The product was isolated by automated Isolera flash
column chromatography (SNAP KP-Sil cartridge, 12-100% EtOAc/Hexanes), to yield
alcohol 3.6 (357 mg, 60%) as a pale yellow amorphous solid. 1H NMR (400 MHz, CDCl3):
δ 7.32-7.10 (m, 8 H), 6.84 (d, J = 12.6 Hz, 1 H), 6.62 (d, J = 12.6 Hz, 1 H), 5.59 (d, J =
14.5 Hz, 1 H), 4.37 (d, J = 14.9 Hz, 1 H), 3.84 (d, J = 14.1 Hz, 1 H), 3.43 (d, J = 15.5 Hz,
1 H), 3.31 (br t, J = 4.3 Hz, 1 H).
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C NMR (100 MHz, CDCl3): δ 171.7, 137.5, 137.0,

136.1, 133.5, 133.3, 131.5, 130.6, 130.1, 129.0, 128.8, 128.1, 127.6, 127.4, 127.4, 61.1,
54.5. HRMS (CI): m/z calculated for C17H16NO2 [M+H]+ : 266.1176; found: 266.1171.
Prosthetic group precursor branch
1-(11,12-didehydrodibenzo[b,f]azocin-5(6H)-yl)-2-hydroxyethanone (3.7)
A solution of alcohol 3.6 (200 mg, 0.75 mmol) in dry DCM (20 mL) was cooled to 0 °C,
and bromine (116 µL, 2.26 mmol) was added dropwise. The reaction was stirred for one
hour at 0 °C and then quenched with sat. aq. Na2SO3. The mixture was extracted into DCM,
washed with sat. aq. Na2SO3 and brine. The organic fraction was dried over Na2SO4, and
concentrated under reduced pressure. The product was used without further purification.
The crude product was dissolved in dry THF (50 mL) and cooled to -40 °C. A solution of
1 M KOtBu in THF (2.46 mL, 2.46 mmol) was added dropwise and the mixture was stirred
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at -40 °C for 1.5 h. Another aliquot of KOtBu in THF (0.71 mL, 0.71 mmol) was added
and the mixture stirred for a further 30 minutes. The mixture was brought to room
temperature and poured into 100 mL of water. The product was extracted with DCM, and
the combined organic layers were washed with 1M HCl, water and brine. The organic
fraction was dried over Na2SO4, and concentrated under reduced pressure. The product was
isolated by automated Isolera flash column chromatography (SNAP-KP-Sil cartridge, 12100% EtOAc/Hexanes), to yield cyclooctyne 3.7 (82 mg, 41%) as an off-white powder. 1H
NMR (400 MHz, CDCl3): δ 7.71 (d, J = 7.5, 1 H), 7.45-7.28 (m, 7 H), 5.21 (d, J = 14.1 Hz,
1 H), 4.20 (d, J = 16.0 Hz, 1 H), 3.79 (d, J = 14.1 Hz, 1 H), 3.40 (d, J = 16.0 Hz, 1 H), 2.63
(br s, 1 H). 13C NMR (100 MHz, CDCl3): δ 172.6 148.8, 147.3, 132.2, 129.2, 128.7, 128.7,
128.6, 128.3, 127.6, 126.0, 123.2, 123.1, 115.0, 107.3, 60.8, 56.2. HRMS (EI): m/z
calculated for C17H13NO2 : 263.0946; found: 263.0936.
2-(11,12-didehydrodibenzo[b,f]azocin-5(6H)-yl)-2-oxoethyl 4methylbenzenesulfonate (3.8)
A solution of cyclooctyne 3.7 (30 mg, 0.11 mmol), tosyl chloride (32 mg, 0.17 mmol), and
triethylamine (48 µL, 0.33 mmol) in DCM (5 mL) was stirred for 24 hours. The mixture
was diluted with DCM, washed with 1 M HCl, water, and brine. The organic fraction was
dried over Na2SO4, and concentrated under reduced pressure to yield tosylate 3.8 (40 mg,
80%) as an orange solid. The product was stored under a nitrogen atmosphere at -20 °C
prior to use in radiolabelling. 1H NMR (400 MHz, CDCl3): δ 7.66-7.25 (m, 10 H), 7.21 (d,
J = 7.9 Hz, 2 H), 5.16 (d, J = 13.9 Hz, 1 H), 4.62 (d, J = 13.9 Hz, 1 H), 4.07 (d, J = 13.9
Hz, 1 H), 3.67 (d, J = 13.9 Hz, 1 H), 2.39 (s, 3 H). 13C NMR (100 MHz, CDCl3): δ 165.0,
149.4, 147.0, 145.0, 132.7, 132.6, 129.8, 129.2, 128.9, 128.5, 128.4, 128.2, 128.1, 127.7,
125.8, 123.3, 122.9, 115.3, 107.5, 65.7, 56.0, 21.8. HRMS (EI): m/z calculated for
C24H19NO4S : 417.1035; found: 417.1031.
Standard branch
(Z)-1-(dibenzo[b,f]azocin-5(6H)-yl)-2-fluoroethanone (3.9)
To a solution of 3.5 (736 mg, 2.25 mmol) in acetonitrile (10 mL), a 1 M solution of TBAF
in THF (4.50 mL, 4.50 mmol) was added dropwise. The reaction was stirred overnight and
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then solvent was removed under reduced pressure. The organic fraction was dissolved in
DCM, washed repeatedly with water, dried over Na2SO4 and concentrated under reduced
pressure. The product was isolated by automated Isolera flash column chromatography
(SNAP-KP-Sil cartridge, 12-100% EtOAc/Hexanes), and 3.9 was obtained as a yellow
solid (600 mg, quant.). 1H NMR (400 MHz, CDCl3): δ 7.32-7.10 (m, 8 H), 6.86 (d, J =
12.6 Hz, 1 H), 5.56 (d, J = 14.9 Hz, 1 H), 4.62 (dd, J = 47.4, 13.8 Hz,1 H), 4.32 (d, J =
15.3, 1 H), 4.31 (dd, J = 46.8, 13.9 Hz, 1 H). 13C NMR (100 MHz, CDCl3): δ 166.4 (d, 2JCF
= 20 Hz), 137.9, 136.8, 136.2, 133.5, 131.4, 130.9, 130.4, 128.9, 128.8, 127.9, 127.6, 127.4,
127.3, 79.1 (d, 1JCF = 177 Hz), 54.2. HRMS (EI): m/z calculated for C17H14FNO : 267.1059;
found: 267.1056.
1-(11,12-didehydrodibenzo[b,f]azocin-5(6H)-yl)-2-fluoroethanone (3.10)
A solution of 3.9 (600 mg, 2.25 mmol) in dry DCM (40 mL) was cooled to 0 °C, and
bromine (346 µL, 6.75 mmol) was added dropwise. The reaction was stirred for one hour
at 0 °C and then quenched with sat. aq. Na2SO3. The mixture was extracted into DCM,
washed with sat. aq. Na2SO3 and brine. The organic fraction was dried over Na2SO4, and
concentrated under reduced pressure. The product was used without further purification.
The crude product was dissolved in dry THF (50 mL) and cooled to -40 °C. A solution of
1 M KOtBu in THF (7.00 mL, 7.00 mmol) was added dropwise and the mixture was stirred
at -40 °C for 1.5 h. Another aliquot of KOtBu in THF (2.00 mL, 2.00 mmol) was added
and the mixture stirred for a further 30 minutes. The mixture was brought to room
temperature and poured into 100 mL of water. The product was extracted with DCM, and
the combined organic layers were washed with water and brine. The organic fraction was
dried over Na2SO4, and concentrated under reduced pressure. The product was isolated by
automated Isolera flash column chromatography (SNAP-KP-Sil cartridge, 12-100%
EtOAc/Hexanes), to yield cyclooctyne 3.10 (380 mg, 55%) as a yellow solid. 1H NMR
(400 MHz, CDCl3): δ 7.72 (d, J = 7.5, 1 H), 7.44-7.26 (m, 7 H), 5.23 (d, J = 13.9 Hz, 1 H),
4.85 (dd, J = 47.3, 13.5 Hz, 1 H), 4.34 (dd, J = 46.9, 13.5 Hz, 1 H), 3.71 (d, J = 13.9 Hz, 1
H). 13C NMR (100 MHz, CDCl3): δ 167.1 (d, 2JCF = 20 Hz), 149.3, 147.1, 132.6, 129.0,
128.7, 128.6, 128.2, 128.2, 127.6, 125.6, 123.2, 123.0, 115.4, 107.5, 78.9 (d, 1JCF = 177
Hz), 55.8. HRMS (EI): m/z calculated for C17H12FNO : 265.0903; found: 265.0893.
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3.4.3

Peptide Synthesis

Dpr3(alloc),Lys19(N3)-ghrelin(1-19) and (D-Phe6,β-Ala11,Phe13,Nle14)-Bombesin(6-14)
peptides were synthesized using standard Fmoc SPPS conditions on the Biotage SyroWave
automated peptide synthesizer. Fmoc-protected Rink amide MBHA resin was used as a
solid support after swelling in DCM. Fmoc removal was achieved using 40% piperidine in
dimethylformamide (DMF) over two steps (30 sec and 12 min). Amino acids were coupled
with 4 equivalents of the Fmoc-protected amino acid, 4 equivalents of HCTU and 8
equivalents of N,N-diisopropylethylamine (DIPEA) in DMF/N-methyl pyrrolidinone
(NMP) over 1 hour. Alloc removal was achieved with 24 equivalents of phenylsilane and
0.1 equivalents of tetrakis(triphenylphosphine) palladium (0) in dry DCM. Octanoic acid
was manually coupled to the diaminopropionic acid side chain using 3 equivalents of
octanoic acid, 3 equivalents of HCTU and 6 equivalents of DIPEA in DMF. N3-(PEG)7COOH (NovaBioChem) was manually coupled to the N-terminus of (D-Phe6,βAla11,Phe13,Nle14)-bombesin(6-14) using the above standard coupling conditions.
Full cleavage of the azido-peptides from resin along with removal of side chain protecting
groups was achieved with a solution of TFA (95%), triisopropylsilane (TIPS) (2.5%), and
water (2.5%) over 5 h. The cleaved peptide was precipitated in cold tert-butyl methyl ether
(TBME) and centrifuged at 3000 rpm for 15 min. The TBME was decanted, the peptide
dissolved in water, frozen at -78 °C and lyophilized. The azido-peptides were then purified
by preparative reverse-phase HPLC-MS over a gradient of 30-80% acetonitrile (0.1%
TFA) in water (0.1% TFA). The peptides were isolated in >98% purity by analytical RPHPLC.
Dpr3(octanoyl),Lys19(N3)-ghrelin(1-19) (3.11)

HRMS (ESI): m/z calculated for C102H168N36O30 [M + H]+: 2378.2805; found: 2378.2839.
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Figure 3.3 Analytical UV chromatogram from RP-HPLC of purified 3.11 (25-80%
ACN/H2O, 0.1% TFA, 10 minutes, RT = 8.69 min).
(D-Phe6,β-Ala11,Phe13,Nle14)-Bombesin(6-14)-PEG8(N3)

HRMS (ESI): m/z calculated for C79H117N18O21 [M + H]+: 1653.8641; found: 1653.8605.

Figure 3.4 Analytical UV chromatogram from RP-HPLC of purified (D-Phe6,βAla11,Phe13,Nle14)-Bombesin(6-14)-PEG8(N3) (30-85% ACN/H2O, 0.1% TFA, 10
minutes, RT = 9.30 min).
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Dpr3(octanoyl),Lys19(triazole-ADIBO-F)-ghrelin(1-19) ([19F]3.12)

Azido-ghrelin peptide 3.11 (10 mg, 3.39 µmol) was dissolved in 1 mL of a 3:2 EtOH/H2O
solution. ADIBO-F 3.10 (1 mg, 3.77 µmol) was added and the solution was stirred for 5
hours, diluted with water, frozen and lyophilized. The peptide was purified by preparative
RP-HPLC, with no difference in retention time between the two regioisomers (25-80%
ACN/H2O, 0.1% TFA). The non-radioactive fluorine-19 containing ghrelin standard
[19F]3.12 was obtained (4 mg, 37%, >98% purity by analytical HPLC) as a 5∙TFA salt. One
regioisomer of 3.12 is shown. HRMS (ESI): m/z calculated for C119H181FN37O31 [M + H]+:
2643.3708; found: 2643.3582.

Figure 3.5 Analytical UV chromatogram from RP-HPLC of purified [19F]3.12 (25-80%
ACN/H2O, 0.1% TFA, 10 minutes, RT = 9.15 min).
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(D-Phe6,β-Ala11,Phe13,Nle14)-Bombesin(6-14)-PEG8(triazole-ADIBO-F)

Azido-bombesin peptide (6 mg, 3.39 µmol) was dissolved in 1 mL of a 3:2 EtOH/H2O
solution. ADIBO-F 3.10 (1 mg, 3.77 µmol) was added and the solution was stirred for 5
hours, diluted with water, frozen and lyophilized. The peptide was purified by preparative
RP-HPLC, with no difference in retention time between the two regioisomers (25-80%
ACN/H2O, 0.1% TFA). The non-radioactive fluorine-19 containing bombesin standard
was obtained (2 mg, 30%, >98% purity by analytical HPLC) as a TFA salt. One
regioisomer is shown. HRMS (ESI): m/z calculated for C96H129FN19O22 [M + H]+:
1918.9544; found: 1918.9551.

Figure 3.6 Analytical UV chromatogram from RP-HPLC of purified (D-Phe6,βAla11,Phe13,Nle14)-Bombesin(6-14)-PEG8(triazole-ADIBO-F) (35-80% ACN/H2O, 0.1%
TFA, 10 minutes, RT = 9.22 min).
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3.4.4

Radiochemistry

All radiochemical yields are determined for the isolated product and are decay-corrected.
All radiochemical purities are determined by radio-HPLC analysis of the isolated product.
Fluorine-18 was trapped on a Waters QMA carbonate SepPak. The activity was eluted into
a vial with a solution of 2 mg potassium carbonate and 8 mg of kryptofix 222 in 200 µL of
MilliQ water and 800 µL of ACN. The solution was evaporated to dryness on a Biotage
Speed Rotary Evaporator and further dried azeotropically with 1 mL of ACN, repeated
twice. The dried fluoride-18 was then transferred in two 150 µL washes of ACN to a
reaction vial containing 1 mg of the tosylate precursor 8. This was allowed to react at 80
°C for 10 minutes. The crude reaction mixture was then diluted with 300 µL of MilliQ
water and loaded onto a semi-preparative column (50% ACN/H2O 0.1% TFA). The
ADIBO-F prosthetic group [18F]3.10 was isolated in 21-35% decay-corrected
radiochemical yields in greater than 98% purity. The identity of [18F]3.10 was confirmed
by co-injection with the non-radioactive standard 3.10 showing a consistent retention time
of 6.5 minutes.

Figure 3.7 Overlaid analytical RP-HPLC UV chromatogram at 220 nm of [19F]3.10
(dashed) and radio-chromatogram of [18F]3.10 (solid) (50% ACN/H2O 0.1% TFA).
[18F]ADIBO-F [18F]3.10 collected semi-preparatively was dried on a Biotage Speed Rotary
Evaporator. To this vial, 2 mg of either Dpr3(octanoyl)Lys19(N3)-ghrelin(1-19) (3.11) or
(D-Phe6,β-Ala11,Phe13,Nle14)-bombesin(6-14)-PEG8(N3) in 200 µL of a 1:1 solution of
MilliQ water and ACN was added. This was heated at 70 °C for 15 minutes. The crude
reaction mixture was diluted with 300 µL of MilliQ water and loaded onto a
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semipreparative column (25 to 80% ACN/H2O, 0.1% TFA) In either case, retention time
between regioisomers was indistinguishable. The labelled peptides were isolated in 6466% ([18F]3.12) or 81-88% decay-corrected radiochemical yields, respectively, with
greater than 98% radiochemical purity. Their identities were confirmed by analytical
HPLC co-injection with their nonradioactive analogues with consistent retention times at
4.5 or 6.6 minutes, respectively.

Figure 3.8 Overlaid analytical RP-HPLC UV chromatogram at 220 nm of standard (DPhe6,β-Ala11,Phe13,Nle14)-Bombesin(6-14)-PEG8(triazole-ADIBO-F) (dashed) and radiochromatogram of [18F](D-Phe6,β-Ala11,Phe13,Nle14)-Bombesin(6-14)-PEG8(triazoleADIBO-F) (solid) (25 to 80% ACN/H2O, 0.1% TFA).
Molar activities for the isolated labelled peptides were determined based on the area under
the curve (AUC) for the UV absorption at 220 nm. A calibration curve for each peptide
was constructed from varying concentrations of the nonradioactive analogue (R2>0.99).
For the ghrelin peptide, 10 µL of 0.0125-0.5 mg/mL solutions of [19F]3.12 were injected
onto an analytical column running a gradient of 25 to 80% (ACN/H2O, 0.1% TFA) over
15 minutes. For the bombesin peptide, 10 µL of 0.0125-0.1 mg/mL solutions were injected
onto an analytical column running a gradient of 25 to 80% (ACN/H2O, 0.1% TFA) over
15 minutes. Molar activities for the isolated labelled peptides were then determined from
the total activity collected and volume of the fraction collected semipreparatively, and the
AUC for a 10 µL aliquot of the collected fraction run on the same gradient. This gave rise
to molar activities of 0.6-0.9 GBq/µmol for [18F]3.12, and 0.6-1.1 GBq/µmol for the
labelled bombesin peptide.
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3.4.5

In Vitro Competitive Binding Assays

GHSR-1a
In vitro GHSR-1a affinity for [19F]3.12 was determined through a competitive binding
assay using HEK293 cells transiently transfected to express GHSR-1a and [125I]Ghrelin as
the GHSR-1a-specific radioligand. The compound of interest (30 µL, at concentrations
ranging from 10-11 to 10-5 M) and 15,000 cpm of [125I]Ghrelin were mixed with the binding
buffer (25 mM HEPES, 0.4% BSA, 5 mM MgCl2, 1 mM CaCl2, 1 mM EDTA in H2O, pH
7.4) in 1.5 mL Eppendorf vials. A suspension of 50,000 HEK293 cells in 50 µL binding
buffer was added to each vial to give a final volume of 300 µL.
GRPR
In vitro GRPR affinity for the standard (D-Phe6,β-Ala11,Phe13,Nle14)-bombesin(6-14) and
(D-Phe6,β-Ala11,Phe13,Nle14)-bombesin(6-14)PEG8(triazole-ADIBO-F) was determined
through a competitive binding assay using PC-3 cells and [125I]Tyr4-Bombesin as the
GRPR-specific radioligand. PC-3 cells were grown in Ham’s F-12K medium
supplemented with 10% fetal bovine serum. The compound of interest (30 µL, at
concentrations ranging from 10-12 to 10-5 M) and 20,000 cpm of [125I]Tyr4-Bombesin were
mixed with the binding buffer (25 mM HEPES, 0.4% BSA, 5 mM MgCl2, 1 mM CaCl2, 1
mM EDTA in H2O, pH 7.4) in 1.5 mL Eppendorf vials. A suspension of 500,000 PC-3
cells in 50 µL binding buffer was added to each vial to give a final volume of 300 µL.
In each binding assay the vials were shaken at 550 rpm for 20 minutes at 37 °C.
Immediately after the incubation, the vials were centrifuged at 13,000 xg, and the
supernatant removed. The cell pellet was washed with 500 µL of 50 mM Tris buffer (pH
7.4), centrifuged again, and the supernatant was removed. The amount of [125I]-radioligand
bound to the cells was measured using a gamma counter (Perkin-Elmer). IC50 values were
determined by nonlinear regression analysis to fit a 4-parameter dose response curve using
GraphPad Prism (Version 6.0c). All data points were obtained in triplicate. IC50 values
were

as

follows:

[19F]3.12,

9.7

nM;

(D-Phe6,β-Ala11,Phe13,Nle14)-bombesin(6-

14)PEG8(triazole-ADIBO-F), 0.50 nM; and (D-Phe6,β-Ala11,Phe13,Nle14)-bombesin(6-14),
0.70 nM.
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Figure 3.9 Binding curve for the competitive binding assay of [19F]3.12 in HEK293GHSR-1a cells. The IC50 value determined was 9.7 nM.

Figure 3.10 Binding curves for the competitive binding assay of standard (D-Phe6,βAla11,Phe13,Nle14)-bombesin(6-14) (red), and of (D-Phe6,β-Ala11,Phe13,Nle14)bombesin(6-14)PEG8(triazole-ADIBO-F) (black) with PC3 cells. The IC50 values
determined were 0.70 and 0.50 nM, respectively.
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Chapter 4

4

Synthesis and Screening of a Combinatorial Library of
Fluorine-Integrated Peptides for PET Imaging Agent
Discovery

4.1 Introduction
Advances in the fields involving molecular imaging are increasingly allowing for noninvasive imaging of biological processes and markers related to a variety of disease states.
Imaging of specific targets can aid in diagnosis and staging of disease, as well as predicting
and monitoring response to targeted treatment. This is an especially advantageous tool with
the advent of personalized medicine wherein knowledge of the presence of specific
biomarkers can determine course of treatment. For imaging modalities such as positron
emission tomography (PET), the scope and progression of its clinical relevance depends
on the development of new radiopharmaceutical agents towards an expanding variety of
targets.
Peptides are especially useful as the targeting ligand component of PET
radiopharmaceuticals because they are easy to synthesize and modify, have biological halflives that match those of the radioisotopes used, and often have high specificity and
selectivity towards their target.1 Peptide radiopharmaceuticals can be constructed through
rational design or discovered through screening campaigns of libraries of compounds. In
the former, the radiopharmaceutical is designed by modifying a known ligand of the target
or designing a peptide based on the microenvironment of the target. In contrast, screening
campaigns can be undertaken which lead to the discovery of new targeting ligands, which
is impactful when the target is unknown, there are no known ligands for a target, or those
that exist do not have an appropriate pharmacokinetic profile for imaging. Common
methods include high-throughput screening (HTS) of compound libraries, in silico
screening of libraries, or screening of combinatorial libraries such as one-bead onecompound (OBOC) or phage display.
The synthesis of OBOC libraries through a split-and-mix approach creates libraries of
millions of unique peptides on-resin, where each resin bead hosts multiple copies of a
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single random peptide sequence.2 Screening these beads against targets of interest has
resulted in the successful identification of peptides targeting cancer biomarkers and other
disease states.3–7 Unfortunately, peptides discovered from these libraries have only rarely
been converted into imaging agents, as appending an imaging moiety often leads to a
decrease in the target affinity observed during the library screen.8–15 An OBOC library is a
useful combinatorial approach in that they are synthesized via solid-phase peptide synthesis
(SPPS), and unnatural peptide modifications are trivial to include. Surprisingly, only a few
descriptions exist where an imaging component was included in the synthesis of an OBOC
library; in all cases, the imaging moiety was appended to a terminal of the peptides or
peptoids.16–18 Screening of an imaging agent library would allow for the discovery of new
radiopharmaceutical imaging agents where the imaging moiety is already accounted for in
target binding.
Bioconjugation through click chemistry is a popular technique for radiolabelling of PET
imaging agents because of its fast reaction kinetics, physiologically friendly reaction
conditions and significantly reduced byproducts.19 A particularly interesting click reaction
is the strain-promoted alkyne-azide cycloaddition (SPAAC) which is a substitute for
traditional copper-catalyzed click chemistry reactions using strained cyclooctynes,
avoiding the use of cytotoxic copper and its consequential removal thereafter.20–22
As stated previously, there is a need for new receptor-targeted PET agents, and a recent
exciting target is the CXCR4 chemokine receptor that has been implicated in over 23 types
of cancer.23 CXCR4 has only two known endogenous ligands, SDF-1α (also known as
CXCL12) and ubiquitin.24 Together CXCR4 and SDF-1α are known to have roles in
chemotactic and angiogenic pathways, which corresponds to the expression of CXCR4 in
metastatic cancers. While CXCR4 is normally expressed in bone marrow, the spleen,
thymus, lymph nodes, pituitary gland, and adrenal glands at low rates, its expression is
significantly higher in malignant tissue compared to healthy adjacent tissues. These aspects
make it an interesting target for imaging of CXCR4-expressing cancers.25 Current peptidebased radiopharmaceutical imaging agents for CXCR4 were all developed from
polyphemusin II, an antimicrobial peptide found in horseshoe crab extracts (Tachypleus
tridentatus). Structure-activity studies and truncation of this peptide resulted in T140, a 14
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amino acid peptide with a single disulfide bond with nanomolar affinity for CXCR4.26,27
Radiolabelling of T140 with fluorine-18 has been performed on the N-terminus or the Lys7
side chain with various prosthetic groups. In many cases, non-CXCR4 specific binding to
red blood cells or significant liver and kidney uptake was observed which limits their utility
as targeted imaging agents.28–30 A novel cyclic pentapeptide, FC131, was derived from the
most important binding residues of T140.31 It has been modified to contain a DOTA
chelator, which has been radiolabelled with 68Ga (Pentixafor), and is now being explored
as a tool to image a variety of CXCR4-expressing cancers in humans.32–34 In the
development of a fluorine-18 version of FC131, the ligand was radiolabelled via a click
reaction on a side chain, but has not yet been explored for in vivo biodistribution or
imaging.35 Unsurprisingly, due to the rational design approach in which all the peptides
were all derived from the same starting peptide, they have similar biodistribution properties
in vivo. The use of combinatorial libraries could lead to the discovery of imaging agents
targeting CXCR4 with a different pharmacokinetic profile (Chapter 2).
Herein, we describe an OBOC library in which fluorine has been randomly inserted within
the peptide side chains. The use of converging and diverging pools during synthesis allows
for the imaging component to be included exactly once in each peptide sequence. The
imaging component is distributed evenly among the eight positions in the octamer peptides;
the remaining seven amino acids are randomized using fifteen different natural amino
acids. Screening of the library against the target CXCR4 will thus result in the discovery
of peptides where the imaging component is included in ligand-target interactions. Notably,
the fluorine has been incorporated into the peptide structure through a SPAAC reaction
using the non-radioactive standard of a recently reported fluorine-18 prosthetic group.36
This design allows for hits from the library to be simply and directly translated into their
fluorine-18 counterpart for PET imaging.

4.2 Results and Discussion
4.2.1

Library Design

Although high-throughput techniques such as combinatorial OBOC libraries are effective
at identifying potential ligands for receptor targeting, these technologies are rarely adapted
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into the discovery of complete imaging agents.16-18 By incorporating an imaging
component directly into such a library, screening for target affinity will involve the entire
imaging agent and no major post-screening modifications should be necessary. Our library
design sought to integrate the imaging entity within the peptide structure, rather than
simply appending the imaging component onto one of the peptide termini away from
potential binding interactions. We chose to design a library of potential PET imaging
agents, using a non-radioactive surrogate containing fluorine-19. Fluorine-19 takes the
place of fluorine-18, which is an important radioisotope commonly used in PET imaging
due to its half-life (~ 110 min), high abundance of positron decay and availability from
cyclotrons. In addition, fluorine-18 can be incorporated into biomolecules via carbonfluorine bonds, which has decreased bulk and increased in vivo stability compared to some
other radiolabels. We chose to use copper-free click chemistry for simple translation of our
hit peptides into imaging agents for PET imaging using SPAAC radiolabelling. We
developed a relatively small fluorine-containing azadibenzocyclooctyne (ADIBO-F) that
can be radiolabelled with fluorine-18 and incorporated into an azide-containing amino acid
side chain to produce a cyclooctatrizaole-fluorine-containing residue.36 Fmoc-protected
azide-containing amino acids such lysine azide are widely available commercially and
therefore amenable to including in the SPPS of an OBOC library (Figure 4.1).

Figure 4.1 Incorporation of an 18/19F-ADIBO-F into a lysine-azide residue in a peptide.
Although amino acids in an OBOC library are traditionally incorporated equally at each
coupling step, including a lysine azide in such a way could result in peptides in the library
containing multiple or, more likely, zero azide functional groups, and subsequently
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multiple or zero locations of the fluorine imaging component. Unfortunately, hits such as
these would limit the utility of the library, as hits may have to be modified to include an
imaging component after all. We decided to design an octamer library that included setting
the location of the lysine azide at each of the eight residue positions. Instead of creating
and screening eight separate libraries, we chose to design a two-pool technique that would
allow for the synthesis of these eight “mini-libraries” at once (Figure 4.2). In brief, at each
coupling step, one eighth of the initial library mass is diverted from the original pool to the
lysine azide pool to ensure even distribution of the imaging component through the eight
residue locations. Initially, one eighth of the library pool is separated and coupled to lysine
azide. After coupling with lysine azide the beads are placed into a separate “lysine azide”
pool (Figure 4.2, top cascade, pool 2). The remaining seven eighths of the library in the
original pool (Figure 4.2, bottom cascade, pool 1) undergo a traditional split-and-mix step
with n natural amino acids in n wells. All beads are combined in their respective separate
pools for Fmoc deprotection and mixing between coupling steps. For the second coupling
step, another eighth of the initial library size is separated from pool 1 and coupled to lysine
azide. All remaining beads in both pools 1 and 2 undergo traditional split-and-mix steps in
their respective pools. The newly azide-containing peptides are then added to the rest of
the dipeptides in pool 2. This process continues for eight coupling, mixing and deprotection
steps where resin switches pools after azide incorporation to ensure only a single azide is
present in each library bead sequence. After eight coupling cycles, the resin is all in pool
2. At this point, each peptide in the library contains a single azide and can be conjugated
to our non-radioactive ADIBO-F prosthetic group surrogate to incorporate an imaging
moiety into the entire library. By using 15 amino acids for the split-and-mix steps, the
theoretical library diversity is around 1.37 billion unique amino acid sequences (= 8 x 157).
In 1.5 million beads, there is only around 0.1 % of the potential sequences expressed, and
thus no redundancy is likely. Therefore, the result of this synthesis cascade is a library of
approximately 1.5 million potential peptide-based imaging agents that should each express
a different peptide sequence and contain a single imaging moiety.
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Figure 4.2 Synthesis cascade showing two-pool split-and-mix SPPS steps to incorporate
a lysine-azide into a library of octapeptides in single random position. This allows a
fluorine-containing cyclooctyne (ADIBO-F) to be globally clicked to the library to
produce a library of on-bead imaging agents.
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4.2.2

Library Synthesis

The library was synthesized on one gram of amine-functionalized Tentagel resin (~1.5
million beads), due to its loading, amenability to aqueous solvents, and uniform size of
beads. All peptides were linked to the resin beads using a photocleavable linker ((3‐amino‐
3‐(2‐nitro‐phenyl)propionic acid) (ANP)) and library synthesis and screening was
performed in the dark. This linker allows the peptides to stay attached to the bead during
side chain deprotection, while also allowing for cleavage from the hit beads under UV light
for peptide sequence determination. The library was then synthesized using SPPS using
the synthesis cascade as described above (Figure 4.2). Fifteen natural Fmoc-amino acids
were used excluding those that would complicate sequencing by tandem mass spectrometry
(MS/MS): tryptophan, cysteine, and methionine due to their tendency to oxidize; as well
as leucine and glutamine because they are isobaric with isoleucine and lysine. All library
beads were combined at the end, swelled in an acetonitrile/water mixture and 1.5
equivalents of ADIBO-F was added to afford the library of globally clicked products with
a lysine(cyclooctatriazole-F) residue. Side chain protecting groups were removed with a
cocktail of 95% trifluoracetic acid (TFA), 2.5% triisopropylsilane (TIPS) and 2.5% water
and the resin was washed thoroughly. To confirm complete library synthesis on-resin, eight
beads were analyzed by MALDI MS/MS. Since there is an amide bond in the ADIBO
prosthetic group, a m/z ratio of the peptide parent mass minus 61 Da was observed in all
MS/MS spectra. This corresponds to the m/z of the entire peptide missing the 2fluoroacetyl radical fragment of the cyclooctatriazole-F and confirming that the peptides
indeed each contained a clicked triazole component (Figure 4.3).
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Figure 4.3 Sample MS and MS/MS spectra demonstrating presence of an ion fragment
resulting from loss of 61 Da from the parent peptide m/z to confirm inclusion of imaging
component cyclooctatriazole-F.

4.2.3

On-Bead Two-Colour Screen

The imaging agent library was screened by employing a two-colour method wherein the
bead-hosted peptides can be screened for both affinity and selectivity to the target in a
single step.37 As CXCR4 was the target of choice due to its implication in over 23 cancer
types, the cell lines utilized were U87.CD4.CXCR4 as a positive cell line that is transfected
to overexpress the receptor of interest, and U87.CD4 as a control cell line that lacks this
transfection.38 To aid in visualization by fluorescence microscopy, U87.CD4.CXCR4 or
U87.CD4 cells were preincubated with a CellTracker dye (ThermoFisher), Green CMFDA
or Red CMTPX, respectively. In stages, the library was incubated in multiple 6-well plates
at concentrations of ~10,000 beads/well and 200,000 cells/well of each cell line in a total
of 3 mL of serum-free DMEM media. The plates were shaken gently for 1 hour at 37 °C,
at which point receptor-peptide interactions between the cells and beads were fixed with
4% paraformaldehyde. To stop cross-linking, glycine was added to each well, and the entire
library was then combined and rinsed with water and resuspended in phosphate-buffered
saline (PBS). The library was visualized by confocal fluorescence microscopy and 25 beads
that displayed binding with only green fluorescent cells (dye λex/em = 492/517 nm) and not
red fluorescent cells (dye λex/em = 577/602 nm) were manually isolated as CXCR4-selective
hits for further investigation (Figure 4.4). Although hundreds of suitable hit beads were
observed, only 25 beads which appeared to have high affinity to the target were chosen
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from this screening to ease the bottleneck step of manual de novo sequencing to follow.
The beads were rinsed with ethanol to remove bound cells, and then placed into individual
wells of a 96 well plate. These hit beads were swollen in methanol and placed under a
160 W 365 nm UV lamp for 1.5 hours to afford photolysis of peptides from the beads.
Photocleavage of the o-nitrophenyl ANP linker results in a carboxamide at the Cterminal.39 The supernatant was then subjected to MALDI MS/MS for peptide sequence
deconvolution.

Figure 4.4 Representative confocal fluorescence microscopy images of library Tentagel
beads during two-colour screening depicting A) bulk beads B) isolated beads showing
affinity for CXCR4 C) individual bead showing specificity to CXCR4.

4.2.4

MALDI MS/MS De Novo Sequencing of Hits

MALDI MS/MS was chosen as a method of hit deconvolution due its high sensitivity and
because of the cost-effectiveness for sequencing multiple peptide hits. MALDI was
performed using α-cyano-4-hydroxycinnamic acid (CHCA) as the matrix, the highest
intensity peaks were chosen as the parent MS and fragmented to produce MS/MS spectra
for each peptide. Peptides predictably fragment through the polyamide backbone in a
collision cell, which allows for comparison of mass differences between ion peaks to
masses of amino acid residues to determine peptide sequences (Figure 4.5).40 Of the 25
peptides, six showed no MS ion in the mass range of interest for our library constructs
(~1000-1500 Da) (Figure 4.8). Of the remaining, eight sequences (4.1-4.8) were fully
deconvoluted by manual de novo sequencing (Table 4.1).
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Figure 4.5 MALDI MS/MS deconvolution of hit peptide imaging agent 4.3 showing a
full y series of ions and some b series ions.
Table 4.1 Sequences and IC50 values of hit peptide structures as determined by de novo
MS/MS sequencing. Where X = lysine(cyclooctatriazole-F). Peptides have a free Nterminus and an amidated C-terminus.
NUMBER

SEQUENCE

IC50 (µM)

4.1

H-

E

R

R

H

S

Y

H

X

-NH2

28

4.2

H-

F

A

R

Y

P

A

S

X

-NH2

86

4.3

H-

G

Y

S

E

E

H

G

X

-NH2

109

4.4

H-

A

I

F

H

E

R

V

X

-NH2

≈ 700
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4.5

H-

N

P

R

N

I

E

R

X

-NH2

≈ 700

4.6

H-

N

F

A

H

V

I

X

D

-NH2

>1000

4.7

H-

T

N

D

X

N

H

I

G

-NH2

>1000

4.8

H-

K

N

H

P

V

P

G

X

-NH2

>1000

A sequencing success rate of 42% is not unreasonable for this technique. Incomplete and
non-uniform fragmentation within the peptide backbone limits success and is a known
drawback to this sequencing approach. Complete fragmentation has been described as “a
modern form of surrealism.”41–43 Although databases exist to perform de novo sequencing
of natural peptides, peptides including unnatural amino acids such as the
lysine(cyclooctatriazole-F) moiety in our library require additional input and result in
lengthy and unreliable automated sequencing. It is apparent that a disproportional number
of solvable hit sequences contain the lysine(cyclooctatriazole-F) residue close to or at the
C-terminus of the peptide. This bias likely exists for two reasons. First, sequences with the
bulky cyclooctyne may not be favourable for binding to this particular target, resulting in
hits where this residue is placed close to the bead and is less likely to project into a binding
pocket of the CXCR4 receptor. Secondly, peptide sequences where the high mass residue
is at an end of the peptide appears to result in more complete fragmentation during MS/MS,
which can be partially attributed to better detection capability of ions in the middle of the
mass range analyzed (Figure 4.6). Peptide sequences (4.1-4.8) as determined from MALDI
MS/MS sequencing were re-synthesized on Rink amide resin and purified as their Cterminal amides and once again subjected to MALDI MS/MS at higher (micromolar)
concentrations. MS/MS spectra were compared to those from the library hit bead for
confirmation of accurate structure determination.
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Figure 4.6 MALDI MS/MS showing insufficient fragmentation to deconvolute entire
peptide sequence when the Lys(cyclooctatriazole) residue is centered in the peptide
sequence.

4.2.5

CXCR4 Affinity Determination of Hit Peptides

Re-synthesized, purified peptides were then further tested for affinity by means of insolution in vitro binding assays. Eight peptide sequences (4.1-4.8) were tested using a
competitive radioligand binding assay with U87.CD4.CXCR4 cells and [125I]-SDF-1α as
the radioligand. Binding affinities towards the receptor were determined as IC50 values that
ranged from 28 µM to the mM range (Table 4.1). Three peptides were observed to have
micromolar affinity for the target, while others required millimolar concentrations before
any displacement of the

125

I-ligand was observed. This was an encouraging result as

screening of non-focused libraries typically results in hits with micromolar affinities to the
target, which are then subjected to further lead optimization. Importantly, our three hits
were found to have micromolar affinity to CXCR4 from our combinatorial library of 1.5
million random peptide sequences that include a fluorine moiety. Therefore, further lead
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optimization could be based on straightforward modifications to the peptide sequence and
optimizing in vivo stability, instead of focusing on incorporating an imaging component
without concomitant loss of receptor affinity. Furthermore, we believe that peptide hits
with on-bead CXCR4 affinity yet displaying no or poor affinity to the target based upon
the competitive binding assay, could instead be binding allosterically to the receptor and
would require other methods to reconfirm and evaluate their affinity. Nonetheless, peptide
hits 4.1-4.3 serve as a starting point to continue structure-activity relationship studies to
further optimize new fluorine-containing peptides as CXCR4-binders for PET imaging.
Importantly, peptide 4.3 is particularly interesting; although it does not have the highest
affinity of those studied, it maintains micromolar affinity with only one basic residue and
two acidic residues. Most previously identified CXCR4-binding peptides and small
molecules are highly positively charged due to the negatively charged surface of the
CXCR4 binding pocket,44,45 so this peptide structure presents potential for a new CXCR4
ligand with a unique binding mode and different overall physicochemical properties.

4.3 Conclusions
A unique combinatorial library of fluorine-containing peptides was synthesized using an
OBOC two-pool approach to insert a single imaging component randomly into each
peptide sequence in the library. This library was used to discover potential PET imaging
agents for CXCR4. Three new peptide imaging agents with micromolar affinity and
selectivity to CXCR4 were discovered as initial hits in a single step two-colour library
screen and can undergo lead optimization to improve their CXCR4 affinity. Subsequently,
they can be easily translated into cancer imaging probes by replacing the
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F-moiety in

each hit by labelling the azido-peptides with our established 18F-labelled prosthetic group.
This labelling can be performed in high radiochemical yields and purities due to the nature
of the click reaction. The bottleneck step in hit identification from this library is due to the
laborious and inconsistent process of manual de novo sequencing by MS/MS. Fortunately,
recent advances in OBOC technologies are beginning to ease these challenges,46,47 and our
application could be combined with these new technologies for high-throughput
implementation. This novel type of OBOC library can be used to screen against various
targets to discover new 18F-based PET imaging agents. In addition, any appropriate alkyne-
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based imaging moiety could be clicked into such libraries at the lysine-azide residue to
afford OBOC libraries for a wide variety of imaging applications.

4.4 Experimental
4.4.1

General Experimental

All reagents and solvents were used as received from Sigma-Aldrich, Alfa Aesar, or Fisher
Scientific. Amino acids and resins were received from Peptides International or Chem.
Impex.. ADIBO-F was prepared as previously described.36 Peptides were purified by
preparative reverse-phase HPLC-MS and analytical reverse-phase HPLC-MS was
performed to assess purities. The system consists of a Waters 600 controller, Waters Prep
degasser, Waters Quattro micro Mass, and Waters Mass Lynx software. The UV
absorbance was detected using a Waters 2998 Photodiode array detector. A preparative
column (Agilent Zorbax PrepHT SB-C18 Column 21.2 x 150 mm, 5 µm) or analytical
column (Agilent Zorbax SB-C18 column 4.6 x 150 mm, 5 µm) was used. The solvent
system runs gradients of 0.1 % trifluoroacetic acid (TFA) in ACN and 0.1 % TFA in water
at a flow rate of 20 mL/min or 1.5 mL/min over 10 minutes with a 5 minute wash. After
purification, the collected fractions were frozen at -78 °C and lyophilized. ESI HRMS was
measured on a Bruker microTOF 11.

4.4.2

OBOC Library Synthesis

The library was synthesized using a split-and-mix approach with standard Fmoc solid
phase peptide synthesis (SPPS) conditions on a Biotage SyroWave automated peptide
synthesizer combined with manual peptide coupling steps. Due to the photolabile linker,
synthesis was performed in the dark. Briefly, 1 g of Tentagel S-NH2 resin (90 µm, 0.26
meq/g) was swelled in DCM and manually coupled to Fmoc-ANP-OH linker (4 eq) using
HCTU (4 eq) and N,N-diisopropylethylamine (DIPEA) (8 eq) in DMF for two hours.
Automated Fmoc removal was achieved using 40% piperidine in dimethylformamide
(DMF) over two steps (30 sec and 12 min). The following synthesis cascade approach
follows Figure 4.2. Initially, one eighth of the library was separated (0.0325 mmol) and the
remaining resin was split evenly into fifteen synthesizer vessels. To the 0.0325 mmol of
resin, Fmoc-Lys(N3)-OH was manually coupled (0.13 mmol, 4 eq) with HCTU (4 eq) and
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DIPEA (8 eq) for 2 hours. To the fifteen wells, resin in each well was coupled to a different
Fmoc-amino acid (4 eq) (all natural L-amino acids excluding tryptophan, cysteine,
methionine, leucine and glutamine) using HCTU (4 eq) and DIPEA (8 eq) in DMF for 1.5
hours, followed by automated Fmoc removal and recombination of the resin. Another
0.0325 mmol of resin was separated from this pool, coupled to Fmoc-Lys(N3)-OH as
above, and the rest was split evenly into fifteen synthesizer vessels again. After each
coupling cycle/Fmoc removal cycle, the resin was recombined into one pool, 0.0325 mmol
removed and manually coupled to Fmoc-Lys(N3)-OH and the remainder divided into
fifteen vessels again (until there was no remaining pool). This was repeated eight times to
afford peptides of 1-8 amino acids in length where the Lys(N3) is the N-terminal amino
acid in each separated 0.0325 mmol portion. To finish the synthesis of the peptides as
octamers in length, the initial 0.0325 mmol portion coupled to Lys(N3) was split evenly
into fifteen synthesizer vessels, and resin in each was coupled to a different Fmoc-amino
acid (4 eq) using HCTU (4 eq) and DIPEA (8 eq) in DMF for 1.5 hours. This was followed
by automated Fmoc removal and recombination of the resin, at which point the next 0.0325
mmol azide-containing portion of appropriate peptide length was added to this pool. This
coupling/Fmoc removal cycle was repeated until all peptides were eight amino acids in
length. All library resin was the combined, and ADIBO-F (1.5 eq) was added in a 60:40
ACN/H2O mixture (10 mL) and shaken for 2 hours. The resin was rinsed with DCM (x6).
Full side-chain deprotection was afforded with 95% TFA, 2.5% triisopropylsilane and
2.5% water for 5 hours (20 mL). The library was rinsed thoroughly with DCM, 5%
DIPEA/DMF, DMF, DCM, MeOH, H2O, EtOH, and stored in 70% EtOH/H2O.

4.4.3

Cell Culture

U87.CD4 and U87.CD4.CXCR4 cells were obtained through the NIH AIDS Reagent
Program, Division of AIDS, NIAID, NIH from Dr. Hong Kui Deng and Dr. Dan R.
Littman. U87.CD4.CXCR4 cells were maintained in DMEM – high glucose (Sigma)
containing 15% fetal bovine serum (FBS), 1 μg mL-1 puromycin, 300 μg mL−1 G418, and
1× penicillin–streptomycin. U87.CD4 cells were maintained in DMEM – high glucose
(Sigma) containing 10% FBS, 300 μg mL−1 G418, and 1× penicillin–streptomycin. All cell
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lines were cultured at 37 °C in humidified atmosphere with 5% CO2 and passaged 2 to 3
times per week.

4.4.4

On-Bead Two-Colour Fluorescent Screening

U87.CD4.CXCR4 cells or U87.CD4 cells at 80% confluency were incubated with 5 µM
CellTracker™ Green CMFDA Dye (ThermoFisher) or 5 µM CellTracker™ Red CMTPX
Dye (ThermoFisher) in serum-free DMEM media for 30 min at 37 °C. Dye was aspirated,
and cells were lifted using an enzyme-free dissociation solution (Sigma). Cells were
counted and resuspended in serum-free DMEM at 200,000 cells/mL. Library beads were
suspended in Dulbecco’s modified eagle medium (DMEM) and dispersed in non-treated
6-well plates at ~20 mg/10,000 beads/well (entire library is ~1.5 million beads). Cells from
each cell suspension were added to each well (1 mL, 200,000 cells each) and total volumes
were brought up to 3 mL with DMEM. Plates were shaken at 550 rpm for 1 hour at 37 °C.
To each well, 0.33 mL of 37% paraformaldehyde was added for a final concentration of
4%. Fixing was quenched after ten minutes by the addition of 2 M glycine to a final
concentration of 20%. The entire library of beads was recombined and rinsed with water
and phosphate buffered saline (PBS) repeatedly then suspended in PBS. The library beads
were dispersed in culture dishes for visualization by fluorescence microscopy. Confocal
fluorescence microscopy was performed on a Nikon A1R Confocal Laser Microscope with
either a 488 nm laser for green fluorescence excitation and the emission range set to 500550 nm and a 561 nm laser for red fluorescence with the emission collected at 600-660 nm.
Beads showing high levels of interactions with only green fluorescent U87.CD4.CXCR4
cells were manually isolated using a micropipette and placed in individual wells of a 96well plate. Beads were then carefully washed multiple times with 95% ethanol to remove
bound cells and visualized to confirm removal of cells.

4.4.5

Photocleavage and MALDI MS/MS

To confirm library synthesis, eight beads were placed in individual wells of a 96 well plate,
swollen in methanol, and placed under a 160 W 365 nm lamp for 1.5 hours to afford
photolysis from the resin. The single bead peptide solutions were approximately nanomolar
in concentration based on <10% cleavage from the 0.26 mmol/g loading of an individual
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bead. MALDI MS/MS was obtained for the highest intensity MS peak and de novo
sequencing was performed to identify peptide sequences.

Figure 4.7 Sample de novo sequencing of a random library peptide of 1177 Da showing
almost complete coverage of b and y ion series.
Twenty-five individual hit beads from the library screen were suspended in 40 µL of
methanol in individual wells of 96-well plates and placed under UV light (160 W, 365 nm)
for 1.5 hours to achieve <10% cleavage from the bead due to the ANP linker. Conversely,
1 mg/mL solutions of purified peptides 4.1-4.3 in acetonitrile were prepared. The solutions
were then mixed with equal parts matrix α-cyano-4-hydroxycinnamic acid (CHCA) in
acetonitrile and placed onto the MALDI target. MALDI TOF/TOF was performed on an
AB Sciex TOF/TOF 5800 by the facility manager of the MALDI Mass Spectrometry
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Facility at the London Regional Proteomics Centre. Mass spectra were obtained and
analyzed for each sample (Figure 4.8). The highest intensity peak in each MS spectra was
subjected to MS/MS analysis and peptide sequences were deconvoluted manually by
examining mass differences between fragment ions in these spectra (Chapter 6 Appendix).
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Figure 4.8 MALDI mass spectra for hit peptides demonstrating A) MS with no ions present
in the mass range of interest for our library, B) MS with multiple ion peaks, and C) MS
with a single parent ion present (and its sodium adduct).
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4.4.6

Hit Peptide Synthesis and Characterization

Peptides were synthesized using standard Fmoc SPPS conditions on the Biotage SyroWave
automated peptide synthesizer. Fmoc-protected Rink amide MBHA resin was used as a
solid support after swelling in DCM. Fmoc removal was achieved using 40% piperidine in
DMF over two steps (30 sec and 12 min). Amino acids were coupled with the Fmocprotected amino acid (4 eq), HCTU (4 eq) and DIPEA (8 eq) in DMF/N-methyl
pyrrolidinone (NMP) over 1 hour. For the clicked peptide analogues 4.1-4.8, ADIBO-F
(1.5 eq) was then added in DCM (3 mL) and shaken for 2 hours.
Full cleavage of the Rink-amide peptides from resin along with removal of side chain
protecting groups was achieved with a solution of 95% TFA, 2.5% TIPS and 2.5% water
over 5 h. The cleaved peptides were precipitated in cold tert-butyl methyl ether (TBME)
and centrifuged at 3000 rpm for 15 min. The TBME was decanted, the peptide dissolved
in water, frozen at -78 °C, and lyophilized. The peptides were then purified by preparative
reverse-phase HPLC-MS over gradients of acetonitrile (0.1% TFA) in water (0.1% TFA).
The peptides were all isolated in >98% purity by analytical RP-HPLC. Peptides are a
combination of the two inseparable regioisomers.
4.1

HRMS (ESI): m/z calculated for C64H84FN23O13 [M + H]+: 1402.6681; found: 1402.6640
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4.2

HRMS (ESI): m/z calculated for C61H77FN16O11 [M + H]+: 1229.6020; found:1229.5989
4.3

HRMS (ESI): m/z calculated for C55H66FN15O15 [M + H]+: 1196.4925; found: 1196.4909
4.4

HRMS (ESI): m/z calculated for C63H85FN18O11 [M + H]+: 1289.6708; found: 1289.665
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4.5

HRMS (ESI): m/z calculated for C59H86FN21O13 [M + H]+: 1316.6776; found: 1316.6728
4.6

HRMS (ESI): m/z calculated for C60H77FN16O12 [M + H]+: 1233.5983; found: 1233.5933
4.7

HRMS (ESI): m/z calculated for C53H70FN17O14 [M + H]+: 1188.5350; found: 1188.5350
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4.8

HRMS (ESI): m/z calculated for C56H76FN17O10 [M + H]+: 1166.6023; found: 1166.5992

4.4.7

Radioligand Competitive Binding Assays

In vitro CXCR4 affinity of hit peptides 4.1-4.8 were determined through competitive
binding assays using U87.CD4.CXCR4 cells with [125I]-SDF-1α as the radioligand (Perkin
Elmer). The compound of interest (30 µL, at concentrations ranging from 10−8 to 10−2 M)
or buffer (30 µL as background control) and 20,000 cpm of [125I]-SDF-1α (20 pM) were
mixed with the binding buffer (20 mM HEPES, 0.5% BSA in PBS, pH 7) in 1.5 mL
Eppendorf Protein LoBind vials. A suspension of U87.CD4.CXCR4 cells (50,000 cells in
50 µL) was added to each vial to give a final volume of 300 μL. The vials were shaken at
550 rpm for 20 minutes at 37 °C. Immediately after the incubation, the vials were
centrifuged at 13,000 rpm for 5 minutes and the supernatant removed. The cell pellet was
washed with 500 μL of 50 mM Tris buffer (pH 7) and centrifuged again. The amount of
[125I]-SDF-1α bound to the cells was measured using a gamma counter (PerkinElmer).
Background uptake of the [125I]-SDF-1α onto vials was subtracted from all assay vials. IC50
values were determined by non-linear regression analysis to fit a 4-parameter dose response
curve using GraphPad Prism (Version 6.0c). All data points were obtained in triplicate.
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Chapter 5

5

Conclusions

5.1 Summary and Outlook
Molecular imaging is a rapidly expanding field due to the advent of new technologies that
can be used for medical imaging. The ability to image cellular and metabolic targets as
markers of disease with nuclear imaging techniques like PET and SPECT allows clinicians
and scientists to learn more about these disease states, establish earlier diagnoses, and
stratify patients based on biomarker presence, allowing for personalized medicine. The
chemokine receptor CXCR4 is an interesting GPCR target that is present in over 23 types
of cancers, while being absent in healthy tissue.1,2 Due to its involvement in chemotactic
and angiogenic pathways, it is a potential marker for metastatic cancers. While some
CXCR4 imaging agents have been developed, the only one to show clinical utility is
[68Ga]Pentixafor, and no ideal fluorine-18 tracers have been yet established.3 This
illustrates the need for the development of a toolbox of radiopharmaceutical imaging agents
for CXCR4 and other markers that can be used to non-invasively determine patient-specific
biomarkers. These new imaging agents can be developed based on a rational medicinal
chemistry design from a known ligand-receptor interaction, which can be a lengthy
process. When no such interaction is known, or the possible structures do not have an
appropriate pharmacokinetic profile for imaging, new candidates must be discovered. This
highlights a need for improved discovery methods with regards to receptor-targeted
imaging agents.
Unfortunately, the well-established high-throughput screening approaches that can be used
to observe new drug-target interactions are not commonly translated into the discovery of
new imaging agents. Ligands discovered from these screening campaigns still need
modification into an imaging agent, which limits the utility of the approach. One-bead onecompound (OBOC) libraries are a combinatorial method for synthesizing peptide
libraries,4 and have the advantage of being able to synthetically incorporate non-amino acid
structures. This approach serves as an ideal scaffold for the design of libraries of imaging
agents.
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In this research we explored the development of libraries of millions of imaging agents that
included a fluorine atom as a surrogate for the placement of fluorine-18. This allows
screening of the libraries to be performed on entire imaging agents, limiting the need for
post-screening modifications. We developed the chemistry for two such libraries, and
chose to employ strain-promoted alkyne-azide cycloaddition click (SPAAC) reactions5 to
incorporate the fluorine in each. This reaction is particularly amenable to radiolabelling
with fluorine-18 and the components can be introduced into peptides in a variety of ways.
In Chapter 2, an OBOC library is described where the imaging moiety was placed on the
N-terminus of the peptides. Since this placement of the imaging surrogate results in it
projecting away from the bead, we proposed this would encourage discovery of imaging
agents where the imaging entity was involved in receptor binding. We employed an
existing SPAAC cyclooctyne as well as a reported azido fluorine PEG-based prosthetic
group. Automated screening of this library against a CXCR4-expressing cell line resulted
multiple hits, of which a hit with micromolar affinity to the receptor was discovered.
Unfortunately, multiple obstacles were encountered during this process which limited the
possibility of utilizing the library to its full ability for high-throughput imaging agent
discovery. Firstly, multiple rounds of screening were necessary to establish high-affinity
hits to the target, and screening was not inherently receptor-specific. Hit peptide sequences
needed to be resynthesized to probe target specificity as well as affirm receptor affinity due
to bead autofluorescence complicating automated screening. Secondly, de novo sequence
deconvolution was hindered due to the high fragmentation percentage in the chosen
cyclooctyne portion of the peptide, limiting observation of complete ion series in MS/MS.
Isobaric amino acids included in the library also caused the need for synthesis of multiple
possible iterations of hit sequences for in vitro affinity assays. We addressed these aspects
in our second-generation imaging agent library described in Chapter 4.
The purpose of the work described in Chapter 3 was to establish a novel fluorine-containing
cyclooctyne that could be incorporated rapidly into azide-containing peptides by SPAAC
for

18

F-radiolabelling. Although other such cyclooctynes exist,6–9 we needed the

cyclooctyne to be small enough to not impede receptor-peptide binding or have variable
binding based on regioisomers, have minimal functionalities that would result in
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fragmentation in MALDI MS/MS, and be synthetically accessible on a large scale for
incorporation into our libraries. This resulted in the design and synthesis of our
azadibenzocyclooctyne ADIBO-F.10 We were able to access this in eight steps, radiolabel
it with fluorine-18 in good radiochemical yields, and showed its utility as a prosthetic group
for radiolabelling biomolecules with fluorine-18 by subsequently clicking it into
established cancer-targeting peptides. We demonstrated that its presence in relatively small
peptides did not impede binding. This is a useful addition to the radiochemist’s toolbox of
prosthetic groups for using mild conditions to afford 18F-labelled biomolecules and other
targeting agents.
Chapter 4 relays the design and synthesis of an OBOC library where the imaging moiety
was able to be randomly dispersed within the peptide sequences. The cyclooctyne
prosthetic group established in Chapter 3 allowed us this opportunity. We also approached
the experimental design with obstacles from Chapter 2 in mind, and sought to overcome
these challenges in this chapter. To this end, some sequencing complications were
mitigated by completely removing isobaric amino acids from the library, and by employing
a new cyclooctyne/azide pair with fewer possible MS/MS fragmentation locations. In
addition, an on-bead two-colour screen11 was employed to search for hit peptide beads with
both affinity and selectivity to the target in one step. This eliminated the need for multiple
in-solution assays for hit confirmation.
Aside from improving the library design, we were also able to demonstrate that multiple
hits with micromolar affinity to the chosen receptor, CXCR4, could be discovered from
this imaging agent library. The on-bead two-colour screening was simple and efficient, and
has potential to be automated.12
The libraries described herein serve as an excellent starting point for the development and
expansion of libraries to find new imaging agents for any given target. Libraries of our
design with other imaging components could be produced for any imaging entity of
interest; this gives the potential to produce libraries of SPECT or PET tracers using other
isotope mimics, MRI contrast agents using paramagnetic metal ions, or optical imaging
agents using fluorescent moieties. Other fluorine-18 prosthetic groups could also be
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explored that are smaller in size and have established radiolabelling methods. An imaging
agent OBOC library with a 4-fluorobenzoyl-containing amino acid as the imaging
surrogate was described recently.13 The fluorine-containing amino acid was fixed at the Cterminus on the beads, and the remaining peptide sequences contained a known binding
motif to the target of interest and was randomized at other locations. This library shows the
promise in designing focused peptide-based imaging agent libraries as a method of lead
optimization where peptide-target interactions have been previously explored. Pairing our
newly designed imaging agent library approach with other classic OBOC approaches
would improve upon any hits obtained from such libraries. For example, making OBOC
libraries that incorporate non-canonical or D-amino acids into the synthesis could also
result in peptide imaging agents that have better in vivo stability. Most research
surrounding OBOC is currently focused on improving the automation of the screening and
hit validation process to make the approach truly high-throughput. Therefore, combination
of our application-based imaging agent OBOC approach with new bead-based screening
technologies would only improve the throughput and efficacy of our discovery process.
Importantly, OBOC technologies are being developed to establish more efficient screening
steps,14,15 improve upon sequencing bottlenecks,16,17 and perform affinity assays from
single bead quantities of peptide.18,19 Others have shown the utility of the OBOC approach
in synthesizing libraries of various small molecules or peptoid structures, which would also
be interesting scaffolds to incorporate an imaging component.20,21
In summary, we have proved the usefulness of OBOC libraries in the discovery of new
imaging agents for CXCR4. Hits with micromolar affinities to CXCR4 were discovered
directly from library screens and are good candidates for lead optimization to improve upon
affinity. New imaging agents for CXCR4 could be important in the early detection of
metastatic cancers, and also in imaging of disease load for late-stage patients. With the
advent of targeted radiotherapy, agents that are capable of imaging widespread metastatic
cancers show potential for transformation into theranostic agents. Incorporating SPAAC
into our library designs gives us the ability to immediately translate direct hits from the
library into the radiolabelled counterparts. As part of this, we also developed a new
synthetically accessible fluorine-18 prosthetic group for SPAAC radiolabelling, which can
be useful for quick, clean 18F-labelling of any azide-modified structure.
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Chapter 6

6

Appendix – Additional Data for Chapter 4

6.1 HPLC Traces for Hit Peptides
Analytical UV chromatogram from RP-HPLC of purified 4.1 (15-85% ACN/H2O, 0.1%
TFA, 10 minutes, RT = 9.21 min).

Analytical UV chromatogram from RP-HPLC of purified 4.2 (25-85% ACN/H2O, 0.1%
TFA, 10 minutes, RT = 7.83 min).
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Analytical UV chromatogram from RP-HPLC of purified 4.3 (20-80% ACN/H2O, 0.1%
TFA, 10 minutes, RT = 8.63 min).

Analytical UV chromatogram from RP-HPLC of purified 4.4 (25-85% ACN/H2O, 0.1%
TFA, 10 minutes, RT = 8.55 min).
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Analytical UV chromatogram from RP-HPLC of purified 4.5 (20-80% ACN/H2O, 0.1%
TFA, 10 minutes, RT = 8.74 min).

Analytical UV chromatogram from RP-HPLC of purified 4.6 (25-85% ACN/H2O, 0.1%
TFA, 10 minutes, RT = 8.98 min).
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Analytical UV chromatogram from RP-HPLC of purified 4.7 (20-80% ACN/H2O, 0.1%
TFA, 10 minutes, RT = 8.64 min).

Analytical UV chromatogram from RP-HPLC of purified 4.8 (20-80% ACN/H2O, 0.1%
TFA, 10 minutes, RT = 8.64 min)
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6.2 IC50 Curves for Hit Peptides
IC50 curve for 4.1

IC50 curve for 4.2

IC50 curve for 4.3
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IC50 curve for 4.4

IC50 curve for 4.5

IC50 curve for 4.6
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IC50 curve for 4.7

IC50 curve for 4.8
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6.3 MALDI MS/MS Deconvolution for Hit Peptides
MALDI MS/MS of 4.1
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MALDI MS/MS of 4.2
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MALDI MS/MS of 4.4
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MALDI MS/MS of 4.5
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MALDI MS/MS of 4.6
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MALDI MS/MS of 4.7
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MALDI MS/MS of 4.8
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